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Lung cancer is the leading cause of cancer-related mortality in the United States because 
of its lack of symptoms until late stages.  It is noted that a 5-year relative survival rate can 
be improved by earlier cancer detection. The currently recommended age of screening by 
the U.S. Preventive Services Task Force may not be optimal, and the recommendations 
are only for smokers. The purpose of this cross-sectional study was to examine the 
association between the stages of presentation of lung cancer and age at diagnosis using 
quantitative research. Using the Surveillance, Epidemiology, and End Results (SEER‒18) 
database, 63,107 records were examined of patients diagnosed with lung cancer between 
2010‒2015 was examined. Chi-squared and logistic regression were used to perform the 
data analyses. The results of both the chi-squared test and logistic regression showed a 
significant association between (1) age at diagnosis and the stages presentation of lung 
cancer after controlling for demographic risk factors; (2) the stages of presentation of 
lung cancer and the demographic risk factors after controlling age; and (3) the stages of 
lung cancer, age at diagnosis, and the demographic risk factors of lung cancer. The 
significant risk of people diagnosed with lung cancer was associated with age and 
demographic factors: gender, race/ethnicity, and geographical region. This study may 
help provide additional information for lung cancer screening with the most effective 
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Chapter 1: Foundation of the Study 
Because many studies have found that the incidence of cancer increase with age 
(Chen et al., 2019; White et al., 2014), studies that evaluate a combination of factors 
provide a better tool to measure age-related factors that contribute to lung cancer 
development based on the stages of lung cancer. However, resources are insufficient for 
attributing age-associated factors to lung cancer. Although lung cancer can be considered 
age-related because the incidence of cancer increases with age, it can also be assumed 
that there is a potential link between age and health impairment based on the length and 
amount of exposure to carcinogens (WHO, 2019). Lung cancer ranks first in cancer 
mortality and second in cancer morbidity among all top ten cancers as cited in 
https://seer.cancer.gov/statfacts/html/all.html (NCI, n. d.). According to the data from the 
SEER program, 228,150 new cases of lung and bronchus cancer were reported in 2019 in 
the United States, and an estimated 142,670 (62%) died of lung or bronchus cancer 
(Siegel et al., 2019). According to data from the National Cancer Institute (NCI, n. d.), at 
least 93% of people who died from lung cancer were aged 55 or older (NCI, 2018). The 
risk factors for lung cancer include smoking, age, gender, race/ethnicity, and 
geographical region (Bakulski et al., 2019; Chu et al., 2018; Fos, 2011; NTP, 2016; 
White et al., 2014; Wagner, Cameron-Smith, Wessner & Franzke, 2016). In the United 
States, the U.S. Preventive Services Task Force (USPSTF) now recommends that high-
risk individuals who are between 45 and 80 years of age and have a history of smoking 
30 packs per year (or those who are current smokers) should have yearly lung cancer 
screening. (Ryan, 2018; USPSFT, 2018). Although cigarette smoking causes lung cancer, 
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age is a risk marker for lung cancer regardless of smoking status and may be an important 
determinant for lung cancer screening. This study therefore investigates the relationship 
between age at diagnosis and stage of lung cancer presentation to determine whether a 
recommendation for lung cancer screening based only on age is necessary. In addition, 
this study can help predict the morbidity and mortality of lung cancer.  
Background of the Problem 
Types of Lung Cancer 
There are two main types of broadly classified lung cancers: non-small-cell-lung 
cancer (NSCLS) constitutes about 70%‒85% cases, and small-cell lung cancer constitutes 
about 15%‒30% of cases (AJCC, 2010; Jin et al., 2018; Lozano et al., 2018).  However, 
most reported cases of lung cancer are NSCLC, which consists of five different subtypes: 
(i) adenocarcinoma, (ii) squamous cell carcinoma, (iii) adenosquamous carcinoma, (iv) 
large cell neuroendocrine carcinoma, and (v) large cell carcinoma (Gingras, M., 2018; 
Zamay et al., 2018). In NSCLC, adenocarcinoma is the most common type seen in both 
smokers and non-smokers (ACS, 2019; Zamay et al., 2018). Adenocarcinoma arises from 
glandular cells of the bronchial mucosa and expresses several protein makers. The 
diagnosis of adenocarcinoma is often based on the identification of molecular markers of 
mutations in epidermal growth factor receptor, ERCC‒1 (DNA excision repair protein), 
RRM‒1, KRAS, TS, and EML4‒Alk (Zamay et al., 2018). Squamous cell carcinoma 
arises from modified bronchial epithelia cells, and one of the most characteristic features 
of squamous cell cancer is high levels of fragmented cytokeratin CK‒19 subunit 
(CYRFA21‒1). The level of CYRFA21‒1 increases during the malignization process of 
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normal epithelia cells and is highly expressed in the serum of patients with a metastatic 
form of squamous cell carcinoma. Adenosquamous carcinoma contains two types of 
cells: (i) squamous cells (thin, flat cells that line certain organs) and (ii) gland-like cells 
(Zamay et al., 2018). Large-cell neuroendocrine carcinoma is a malignant epithelia tumor 
comprised of large poloyonal cells that do not show any evidence of histological 
differentiation (Zamay et al., 2018). The tumor arises from neuroendocrine cells of the 
respiratory tract lining layer or smooth muscle cells of its wall. A large-cell carcinoma is 
a heterogeneous group of undifferentiated malignant neoplasms that lack the cytological 
and architectural features of cell carcinoma and glandular or squamous differential 
(Zamay et al., 2018). Large-cell carcinoma is categorized as a subtype of NSCLC that 
originates from epithelial cells of the lung (Zamay et al., 2018).  
Association Between Smoking and Lung Cancer 
Smoking is associated more with squamous cell carcinoma and small-cell cancers 
than with adenocarcinomas (Stram et al., 2019). An association between exposure to 
cigarette smoke and the development of lung cancer is well recognized; more than 80% 
of lung cancer cases are caused by cigarette smoke (Bakulski et al., 2019; Gingras, M., 
2018; Ni et al., 2018). According to the National Toxicology Program, cigarettes contain 
at least 69 carcinogens that promote cancer in humans (National Toxicology Program, 
2016; Pu, Xu, Zhang, Yuan, Hu, Huang, & Wang, 2017). Since smoking affects DNA 
methylation throughout the genome (Bakulski et al., 2019), the longer a person smokes 
cigarette, the higher the exposure to carcinogens (including carbon monoxide, 
hydrocarbons, ammonia, cadmium, and other substances) that elevate the risk of lung 
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cancer. However, age is a major risk factor for lung cancer, and the death rate of lung 
cancer is higher among middle-aged and older populations (NCI, n. d.). The current 
understanding of age-related factors that contribute to lung cancer is insufficient. 
Although some researchers may not agree that age (as an absolute number) is a risk factor 
for cancer, age-related factors such as a change in the biological materials of DNA can 
contribute to cancer (Adams et al., 2015).  
Association Between Age and Cancer Risk 
Many epidemiology studies have found that age increases the risk of cancer, and 
that human physiological function declines and cell mutations increase with age 
(Bakulski et al., 2019; Kathuria et al., 2014; Swanton et al., 2015; Wagner et al., 2016; 
Yokoyama et al., 2019). Molecular studies have found that multiple alterations and 
damage within molecular pathways increase as age increase (Wagner et al., 2016; Xia & 
Han, 2018; Chen et al., 2017; Yang, D., Yang, K., & Yang, M., 2018). Several cancer 
studies have found that at least 90% of carcinogens are mutagens that increase with age, 
which leads to earlier death (Adams et al., 2015; Smith et al., 2009; Swanton et al., 2015; 
Weiss, 2002; Yancik et al., 2005). Thus, age-related factors could be the most profound 
risk factor for almost all non-communicable diseases, including cancer (Wagner et al., 
2016).  Because physiological function declines as age increases (Adams et al., 2015; 
Wanger et al., 2016; Xia et al., 2018), a single test that measures age-related risk factors 
could predict the future onset of lung cancer (Adams et al. 2015). Although many studies 
found that age-related factors increase the overall risk of cancer, there is still a lack of 
understanding of age-related factors that contribute to lung cancer.   
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Other Risk Factors for Cancer 
Nevertheless, lung cancer is not caused by just a single factor, but a combination 
of internal and external (also known as genetic and environmental) risk factors (Swanton, 
McGranahan, Starrett & Harris, 2015; Wagner et al., 2016; Shao, Liang, Long, & Jiang, 
2017). Cancer development starts at the cellular level and takes approximately 20‒40 
years to develop after cell mutations, based on multiple risk factors (Adams et al., 2015; 
Wagner et al., 2016). The epidemiology of lung cancer studies often includes variables 
besides age such as cigarette smoke, gender, race/ethnicity, genetic factors, and 
geographical regions to find the association with the health problem. Studies focusing on 
gender differences show that more men develop and die from lung cancer than women 
(Dorak & Karpuzoglu, 2012; Ryan et al., 2018). According to the World Health 
Organization (WHO), there is an association between genetics and differences in gender 
(WHO, 2019). For example, multicenter studies confirmed low testosterone exerts in 
84% of lung cancer cases (Hyde et al., 2012; Wagner et al., 2016). In a global study, 
Ryska et al (2018) found the highest age-standardized incidence rates of non-small lung 
cancer in men around the world.  
In race/ethnicity studies, African Americans in the United States had the highest 
rates of lung cancer and were disproportionately affected by lung cancer in terms of 
incidence and survival (David et al., 2016; Ryan et al., 2018). In the exploration of 
genetic study for lung cancer risk, African-ancestry populations show differences in 
disease allele frequency, linkage disequilibrium patterns, and phenotype prevalence 
(David et al., 2016). The percentage of African American men diagnosed with lung 
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cancer each year is approximately 32% higher than among White men, even though 
African American men have similar rates of smoking and they initiate smoking later in 
life on average (David et al., 2016; Ryan, 2018). The higher risk of lung cancer could be 
because African Americans are more susceptible to the effects of carcinogens from 
chemical exposure through employment (Ryan, 2018). Geographical region is another 
possible risk factor for lung cancer; it can affect incidence, survival rates, stage of 
diagnosis, surgical treatment, and availability of screening centers. Although many risk 
factors for lung cancer are known, the morbidity and mortality of lung cancer is still the 
leading cause of public health burdens.  
Problem Statement 
The problem is that the currently recommended age (55‒80 years) for lung cancer 
screening by the United States Preventive Services Task Force (USPSTF) may not be 
optimized to effectively catch early stage lung cancer. Although chest X-rays and 
imaging screening using low-dose computed tomography (LDCT) have decreased the 
risk of lung cancer, the rates of mortality and morbidity of lung cancer remain stable and 
have not significantly decreased over the past decades (Patnaik et al., 2017). By the time 
symptoms appear in imaging screening, lung cancer has already metastasized (Zamay et 
al., 2017).  Survival rates are negatively affected when individuals are not aware of their 
disease because of the lack of signs and symptoms in early stages (Srivastava, 2012). To 
enhance screening methods for the early detection of cancer, studies need to identify how 
age contributes to lung cancer. This dissertation assesses the association between age at 
diagnosis and stages of presentation of lung cancer by examining the SEER Database. As 
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many previous studies have found, age increases the risk of lymph node and distant 
metastasis (Adams et al., 2015; Chen et al., 2019; Yokoyama et al., 2019). This study 
hypothesizes that stages of presentation of lung cancer differ between patients diagnosed 
at different ages. The types of stages of lung cancer within age subgroups are assessed. 
Purpose of the Study 
The purpose of this investigation is to examine the association between the age at 
which lung cancer is diagnosed and the stage of presentation of lung cancer using 
quantitative research. SEER data is used to explore age groups at diagnosis [(45‒49), 
(50‒54), (55‒59), (60‒64), (65‒74), and (75‒84)] and stages of presentation of lung 
cancer. In addition, the effects of gender, race/ethnicity (African American, White, 
Other), geographic location, health behaviors, and gene-environment interaction are 
explored. The presentation of lung cancer includes stage (I, II, III, IV). The results of this 
study may help to provide a recommendation for effective annual lung cancer screening 
of adults aged 45‒80 who are both smokers and non-smokers (Soo et al., 2018). 
Research Questions and Hypotheses 
RQ1: Is there a significant association between age at diagnosis and the stages of 
presentation of lung cancer after controlling for demographic factors: gender, 
race/ethnicity, and geographic region? 
Ho1: There is no significant association between age at diagnosis and the stage of 
presentation of lung cancer after controlling for demographic factors: gender, 
race/ethnicity, and geographic region. 
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Ha1: There is a significant association between age at diagnosis and the stage of 
presentation of lung cancer after controlling for demographic factors: gender, 
race/ethnicity, and geographic region.   
RQ2: Is there a significant association between the stage of lung cancer and 
demographic factors gender, race/ethnicity, and geographic regions after controlling age?  
Ho2: There is no significant association between the stage of lung cancer and 
demographic factors after controlling for age. 
Ha2: There is a significant association between the stage of lung cancer and 
demographic factors after controlling for age.  
RQ3: Is there any significant relationship between the stage of lung cancer and 
age and demographic factors?  
Ho3: There is no significant relationship between the stage of lung cancer and age 
and demographic factors. 
Ha3: There is a significant relationship between the stage of lung cancer and age 
and demographic factors. 
Theoretical Framework 
The theoretical framework for this study was the Cancer Control Continuum 
(CCC), which is an original framework of the NCI (NCI, n. d.).  The goal of using this 
CCC approach was to reduce the risk of lung cancer through early detection. Yabroff et 
al. (2019) examined ways to reduce the cancer burden of the nation by accessing 
healthcare throughout CCC and by making screening methods more effective. Yabroff et 
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al. stated that although having access to health care was the most effective way to reduce 
health burdens caused by cancer, implementing early cancer screening would ensure 
early recognition and a timely response to cancer. Most cases of lung cancer are found in 
a late stage or stage IV (Zamay et al. 2017), and the survival rate for advanced stages of 
lung cancer is approximately 15% (AJCC, 2017). Therefore, the recommendation should 
be updated for vulnerable populations to receive annual preventive screening beginning 
at age 45. If cancer could be caught early, no Americans would suffer from stage IV lung 
cancer―the most advanced stage of lung cancer when cancer has spread to the other part 
of lungs or distant organs, is more difficult to treat, and when the survival rate is 
generally lower. Therefore, this study used CCC framework to provide valuable 
information about how screening age should be updated for early detection of lung cancer 
by prioritizing early detection to increase survivorship. 
The three principles of the CCC framework are to view plans, progress, and 
priorities in terms of cancer etiology, prevention, and detection. Based on these three 
CCC principles, the various stages of cancer are described with respect to etiology, 
prevention, and early detection. The principles helped us identify research gaps about 
age-related factors that contribute to lung cancer. Here, the association between stages of 
lung cancer and age groups was investigated to increase the knowledge of how age can 
be a risk factor for developing lung cancer. 
The second focus of the CCC framework is prevention through screening. For 
high-risk populations (those who are both smokers and older), the USPSTF recommends 
yearly lung cancer screening with low-dose CT and chest X-ray (USPSTF, 2018). The 
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main purpose of the USPSTF is to protect the health of all Americans by making 
evidence-based recommendations about preventive services such as screenings (USPSTF, 
2015). Although imaging screening using LDCT and chest X-ray decreases the risk of 
lung cancer, the rate of mortality and morbidity of lung cancer has not significantly 
decreased over the past decades (NCI, 2018; Patnaik et al., 2017). Because of the 
exposure to low-dose radiation using LDCT and chest X-rays, UPSTF recommends 
discontinuing preventive screening once a person has not smoked for 15 years or 
develops a health problem that substantially limits life expectancy (USPSTF, 2015).  
  The third focus of the CCC framework is detection. Although early detection has 
been a challenge in the research community, additional information is provided in this 
study about the timing of cancer progression from stage I to stage IV based on the age of 
lung cancer patients. There is limited literature on how cancer progresses from stage I to 
stage IV, and how long it takes for cancer to develop after cell mutations. A few studies 
show that cancer development starts at the cellular level and takes approximately 20‒40 
years to develop after cell mutations (Adams et al., 2015; Wagner et al., 2016). While 
researchers are still investigating the connection between mutations and the time frame of 
cancer development, finding an effective method for early detection is crucial for saving 
lives. In previous research studies, the CCC has been a useful framework for early 
detection and prevention of cancer (Yabroff, et al., 2019).  
Effectiveness in screening is another critically important factor for preventing and 
reducing the public health burden, since the symptoms of lung cancer do not appear in the 
early stages. Through early screening, cancer detection can happen before tumors appear 
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in the lungs, increase in size, and metastasize to nearby organs.  This early detection may 
prevent and reduce the rate of mortality and morbidity caused by lung cancer. The 
evaluation of the association between age at diagnosis and demographic factors such as 
gender and race/ethnicity, health behaviors, and gene-environment interactions will help 
us understand where cancers begin and how to detect them at an early stage. 
The CCC framework may reduce the challenge of preventive screening studies by 
explaining the association between well known risk factors and lung cancer at the 
molecular level. The association between cigarette smoking and lung cancer is well 
known, and approximately 87% of deaths among smokers are due to lung cancer 
(Bakulski et al., 2019). However, the literature is limited on how the carcinogens in 
cigarette smoke increase the risk of mutation and how mutations increase with age. 
According to the National Toxicology Program, a cigarette contains at least 69 
carcinogens that promote cancer in humans (National Toxicology Program, 2016). Any 
substance that causes cancer is known as a carcinogen, and exposure to carcinogens may 
arise from ingestion, physical touch, or inhalation (NCI, n. d.). However, harmful effects 
from exposure to carcinogens are based on the concentration and duration of the exposure 
(NCI, n. d.). Gene-environment interaction (changes in DNA and mutations) that can 
contribute to lung cancer is understudied. Many studies have identified biomarkers found 
in the blood that can be used as a sign of a normal or abnormal progression of cancer 
(Srivastava, 2012).  
Taking advantage of modern technology to use public health information may 
help achieve a higher level of confidence for interpreting the biological process. 
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Technology has changed our understanding of cancer development. The CCC framework 
helps us collaborate with others to determine where more resources may be needed. 
Using the underlying framework of CCC, this study investigates how risk factors related 
to age, health behavior, gender, race/ethnicity, geographical location, and gene-
environment-interaction can contribute to the development of lung cancer. The CCC 
framework can improve our understanding of the epidemiology of lung cancer based on 
contributing risk factors and help guide recommendations for screening. In addition, this 
framework can provide information for future blood-based biomarkers screening. 
Nature of the Study 
The nature of this research was a quantitative study using a cross-sectional design 
to examine data from age, stage, and demographic factors. Specifically, the differences in 
age groups and stages of presentation of lung cancer were analyzed. This quantitative 
method includes stages of lung cancer analyses on each age groups and demographic 
factors using chi-squared test. A multinomial regression analysis was also performed to 
explore the effect of one dependent with four subgroups and the four independent 
variables (age at diagnosis, gender, race/ethnicity, geographic region). The chi-squared 
test to determine whether there was any association between stages of lung cancer and 
age groups, whether there was any association between stages of lung cancer and 
demographic risk factors after controlling age, and whether there was any association 
between stages of lung cancer, age, and demographic factors. The association between 
age at diagnosis and the stage of presentation of lung cancer after controlling for 
demographic factor was identified by a chi-squared test. The association between stages 
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of presentation of lung cancer and demographic risk factors of lung cancer after 
controlling for age at diagnosis was identified by chi-squared test. Logistic regression 
was used to obtain odd ratios (OR) and their respective 95% confidence intervals and 
displayed the strong association of the stages of presentation of lung cancer, age at 
diagnosis, and demographic risk factors. 
Definition of Terms 
The Dependent variable:  
1) Stages of Lung Cancer: Stages of lung cancer were based on the collaborate 
stage, which was cancer fields in the SEER program that include size of the 
tumor, extension, and swelling or malignancy of lymph nodes (which are 
small ball-shaped immune system organs distributed throughout the body) 
(NCI, n. d.). The stages of lung cancer were based on clinical (cTNM) (TNM 
= tumor, node, metasteses) and pathological (pTNM) staging. Clinical staging 
is based on the evidence acquired before treatment, including physical 
examination, imaging studies, laboratory test, and staging procedures such as 
bronchoscopy or esophagoscopy with ultrasound directed biopsies (AJCC, 
2010). The presentation of lung cancer stages is defined by where the cancer 
cells are located, the size of the lung cancer tumor, and where cancer has 
spread. The staging of cancer helps provide information about lung cancer 
prognosis; however, it does not predict how long a patient will live (ALA, 
2020). However, patients with stage 0 were excluded from this study. The 
lower the lung cancer stage, the less the cancer has spread (AJCC, 2010). The 
14 
 
types of lung cancer depend on where the malignant tumor (uncontrolled 
growth and damage of healthy cells) arises from different cells such as 
bronchial epithelium, bronchioles, alveoli, or bronchial mucous glands. As 
many factors such as smoking, family history, occupational exposure, and 
genetic background contribute to developing lung cancer, different types of 
lung cancer can occur based on individual risk. Because of unknown causes 
and the diversity in the molecular-biological features of lung cancer, 
identifying the genetic profile that can predispose individuals to a high risk of 
lung cancer will help us better understand and may lead to improved screening 
options. 
i. Stage I: Lung cancer included cancer cells in the lungs and also cancer 
cells that have spread to any lymph nodes. If the lung cancer is in the 
lungs but has not spread to lymph nodes, it is described as stage I. The 
classification of stage I lung cancer included stage IA as (T1a‒N0‒M0), 
(T1b‒N0‒M0), and stage IB as (T2a‒N0‒M0). T1a was a tumor that was 
(~ 2 cm in size) and TIb was (> 2‒3 cm in size).  
ii. Stage II: The classification of stage II lung cancer included stage IIA as 
(T2b‒N0‒M0) T2b was (> 5 – 7 cm in size), (T1a‒N1‒M0), (T1b‒N1‒
M0), (T2a‒N1‒M0), stage IIB as (T2b‒N1‒M0) and (T3‒N0‒M0).  
iii. Stage III: The classification of lung cancer included stage IIIA as (T1a‒
N2‒M0), (T1b‒N2‒M0), (T2a‒N2‒M0), (T2b‒2‒M0), (T3‒N2‒M0), 
(T3‒N2‒M0), (T4‒N0‒M0), and (T4‒N1‒M0), stage IIIB as (T1a‒N3‒
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M0), (T1b‒N3‒M0), (T2a‒N3‒M0), (T2b‒N3‒M0), (T3‒N3‒M0), and 
(T4‒N3‒M0) (> 7 cm in size). 
iv. Stage IV: The classification of lung cancer included stage IV as (AnyT‒
AnyN‒M1a) and (AnyT‒AnyN‒M1b). Stage IV lung cancer is the most 
advanced stage of lung cancer. It indicates that the cancer has spread to 
both lungs and metastasized to distant organs. Because most cases of lung 
cancer are asymptomatic, and current imaging screening methods detect 
only visible and irreversible changes in lung, a late stage of lung cancer 
was the most diagnosed case among all stages of lung cancer (Zamay et al. 
(2017). 
The Independent Variables:  
1) Age at diagnosis: defined as the measurement of the age of the patient at their 
last birthday. Age at diagnosis were groups in 5 year-interval (45‒49), (50‒
54), (55‒59), (60‒64), (65‒74), (75‒79), and (80‒84). 
2) Gender: defined by the chromosomal genotypes and sexual phylotype present 
at birth (NCI, n. d). 
3) Race/ethnicity: defined by specific physical, hereditary, and cultural traditions 
or origins.  
4) Geographical region: based on residency in a SEER geographic catchment 
area at the time of diagnosis, metropolitan areas included (counties in 
metropolitan area of greater than 1 million, counties in metropolitan area of 
250 to 1 million, counties in metropolitan area of less than 250 thousand) and 
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non-metropolitan areas included (non-metropolitan counties adjacent to a 
metropolitan area, and non-metropolitan counties not adjacent to a 
metropolitan areas). Registries collected state, county, zip code, and address 
derived from the census tract. A version of the census tract depended on the 
year of diagnosis.  
SEER: The SEER program database included large amounts of data, and these data were 
representative of the U.S. population. SEER database was supported by the Surveillance 
Research Program (SRP) in NCI’s Division of Cancer Control and Population Sciences 
(DCCPS). The SRP not only provides data but also disseminates reliable population-
based statistics. All the available lung cancer cases from SEER were used, and all 
patients diagnosed with lung cancer between 2010‒2015 were included in the analysis.  
The SEER program is a population-based cancer registry covering approximately 
36.7% of the U.S. population (based on the 2010 Census; Gingras, M., 2018; NCI, n. d.). 
The information provided in SEER is maintained by the NCI and represents an effort to 
reduce the public health burdens of the U.S. population. Some differences may exist 
between the population of patients recorded in the SEER database and the U.S. general 
population; for example, SEER has a higher likelihood of foreign-born persons compared 
with the 2010 U.S. census, and a higher proportion of races/ethnicities other than White 
American and African American populations. To reduce the limitation of knowledge 
about age-related factors that contribute to lung cancer, data from the National Cancer 




Assumption, Delimitation, and Limitation 
Assumptions 
Based on the literature reviews, this project assumes that the following groups 
have a higher risk of being diagnosed with more advanced stages of lung cancer: older 
age groups, men, African American men, and people who live in Kentucky. The results 
also assume that recommending preventive screening beginning at age 45 for nonsmokers 
more frequently catches early stages of lung cancers that may reduce the rate of the 
morbidity and mortality of lung cancer. These assumptions are based on the correlations 
between age at diagnosis, the stages of presentation of lung cancer, and demographic 
factors gender, race/ethnicity, and geographical regions, which are evaluated by 
multinomial analysis using a cross-sectional study. The chi-squared analyses were used to 
analyze contributing factors of independent variables (age at diagnosis) and 
(demographic factors) and dependent variables (stages of presentation of lung cancer: 
stage: I, II, III, and IV). The variables included in this assumption were all based on the 
previous studies and how long it took for cancer to develop and mutate as age increases 
(Adams et al., 2015).  
According to previous studies, it takes approximately 20‒40 years to develop 
cancer after cell mutation (Adams et al., 2015). Several studies also found that 90% of 
cancers are caused by mutations, and mutations increase with age (Adams et al., 2015; 
Swanton et al., 2015; Wagner et al., 2016). Because many studies have found that the 
incidence of cancer increases with age (Chen et al., 2019; White et al., 2014), studies that 
evaluate a combination of factors provide a better tool to measure age-related factors that 
18 
 
contribute to lung cancer development. A combination of both age-related markers and 
cancer stage-related markers can accurately predict the future onset of cancer (Bürkle et 
al., 2015). To describe how to evaluate age-related lung cancer, this study specified those 
age groups of lung cancer by displaying the data of lung cancer in stages. The analysis of 
this study included the correlation between age and the stages of presentation of lung 
cancer, which were all based on TMN stages. This study provided reasonable justification 
because it used only patients who were diagnosed with lung cancer to ensure that it made 
a sound assumption based on the result. The assumption determined a relationship 
between age and stages of lung cancer, helped better understanding of age-related factors 
contributed to lung cancer, and supported existing studies. The results of this study also 
supported the future use of biomarkers of aging to promote effective preventive 
screening. 
Delimitations 
The scope of this dissertation was to discover how age differences affect lung 
cancer by assessing the association between age of diagnosis, gender, race/ethnicity, and 
stages of presentation of lung cancer, health behaviors, and geographic location. As the 
human immune system responds to carcinogens differently based on a person’s age, the 
potential for early treatment response and metastatic patterns may also differ among age 
groups (Zhuang et al., 2017). Many research studies have explored the different 
prognosis outcomes among younger and older age groups (Becker et al., 2015; Chen et 
al., 2019). However, resources were insufficient for attributing age-associated factors to 
lung cancer. Although lung cancer can be considered age-related because the incidence of 
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cancer increases with age, it can also be assumed that there is a potential link between the 
age of an individual and health impairment based on the length and amount of exposure 
to carcinogens (WHO, 2019).  
Limitations 
The SEER data was broadly representative of the U.S. population, although there 
were some differences: patients recorded in the SEER database were more likely to be 
foreign-born compared with the U.S. Census data. To reduce biases, statistical analyses 
were performed based on the target population (lung cancer patients) of the United States 
to compare stages of presentation of lung cancer with age at diagnosis. A large proportion 
of differences in race/ethnicity and age group may increase bias in the statistical analysis. 
However, to reduce the issue of internal validity, this study addressed specific risk factors 
such as stages of presentation of lung cancer among the middle and older age groups of 
the population. Better knowledge of age-related factors is still needed to improve the 
early detection and outcome of cancer. 
Significance of the Study 
This project is unique because it demonstrated how age-related risk factors can 
contribute to lung cancer and how age at diagnosis can help predict the morbidity and 
mortality of lung cancer. As technological innovations have expanded in health screening 
over the past few decades, age-related factors have provided information for next-
generation research studies to find potential markers for early detection, diagnosis, 
monitoring, and therapies (Fenizia, Pasquale, Roma, Bergantino, Iannaccone, & 
Normanno, 2018; Liu, Zhou, & Cao, 2016). Almost all studies of cancer epidemiology 
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have included age as one of the variables in cancer research (White et al., 2014). Yet age-
related factors that contribute to cancer are understudied. Although age can be defined by 
completed units of time or a time-dependent variable (White et al., 2015), physiological 
systems declined as time progresses (Bürkle et al., 2015). 
 Because the incidence of most cancers increases with age, cancer can be 
considered an age-related disease (Bürkle et al., 2017; Wagner et al., 2016; White et al., 
2014). Many cancer studies have found that 90% of cancer development begins at the cell 
level (Adams et al., 2015; Hammond, 2015; Swanton et al., 2015; Wagner et al., 2016). 
Mutations/damage in cells increase with aging, which is a sign of the pathological 
process of cancer and which can be identified as an abnormal biological process in the 
bloodstream (Bürkle et al., 2017). The results from this dissertation added more 
information to existing studies about the association between age-related factors and lung 
cancer. Therefore, age-related factors can be used for detecting lung cancer before it 
appears in imaging. The results from this study provided valuable information that will 
have positive social implications for the scientific community and contribute to future 
research in public health. As public health is multi-faceted for the surveillance of 
vulnerable populations, age-related factors may aid in the diagnosis of asymptomatic 
patients who suffer from lung cancer. Insights from this study should aide in efficient and 
effective future screening studies for early detection of lung cancer. Moreover, it should 
lead to better health outcomes and reduce the public health burden. 
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Social Change Implications  
The results of the statistical analyses provided information about the most likely 
age of diagnosis and the optimal age range for preventive screening. Demonstrating how 
the optimal age at diagnosis contributes to lung cancer can decrease the morbidity and 
mortality of lung cancer and benefit the public health system. Depending on the rate of 
decrease, the lowered medical cost, and the health benefits to patients, earlier screening 
may be a large benefit to society. This study provided statistical data analysis of existing 
information that can draw conclusions about whether the risk of being diagnosed with 
lung cancer in 45 to 49-year-old patients is higher than in other older age groups. The 
results of our data analyses provided a new screening framework to lower the age of lung 
cancer screening, which will result in reduced cost and improved outcomes for lung 
cancer treatment.  
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Chapter 2: Literature Review 
Introduction 
Lung cancer affects more people than any other disease and can develop without 
any symptoms. Lung cancer has a large impact on American public health, and many 
people are not aware of lung cancer until they have symptoms. As the function of 
physiology declines with increasing age, the function of the healthy lung also declines. 
Chronological age is a unit number of times that measures one’s life starting from the day 
one is born. Age alone cannot be a risk factor for cancer (White, 2014). However, age-
related factors that contribute to lung cancer can be measured through physiological 
functional capacity and genetic integrity of adult tissue stem cells that decline as age 
increases (Adams et al., 2015). 
Lung cancer can be considered an age-related cancer, because many research 
studies have shown that the incidence of lung cancer increases with age (Adams et al., 
2015; Bai, 2018; White et al., 2014). Changes in DNA and cell mutations affect 
physiological function that gauge to physical age and are factors that can predict the 
future onset of ill health (Bai, 2018; Popović et al., 2018; White et al., 2014; Xie et al., 
2018). Although a time-dependent physiological functional decline is not preventable as 
age increases, it is possible to intervene and delay the process of aging and reduce the 
incidence of age-related lung cancer (Wang, 2018). As age-related factors change 
biological materials at the cellular level, assessing factors that contribute to lung cancer 
will help elucidate the epidemiology of lung cancer. Many epidemiological studies of 
diseases and cancers included diseases and cancers that mainly occur in older people. The 
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average age of people diagnosed with lung cancer is about 65 (Wagner et al., 2016; 
White, 2014). Yet, age-related factors that contribute to lung cancer have been 
understudied (Wagner et al., 2016; White, 2014).  
To overcome the lack of understanding of the age-related factors that contribute to 
lung cancer, this literature review focuses on variables that are related to lung cancer 
development (such as age at diagnosis, cell mutations, stages of tumors, nodes, and 
metastasis) to assess how human biological age can help explain the epidemiology of 
lung cancer. Several biological studies of cancer studies found that (1) cancer cell 
impairment increases with age, (2) accumulation of carcinogens increases with age, and 
(3) 90% of cancers are caused by cells mutations (ACA, 2015; Adams et al., 2015; 
Hammond, 2015; Adams et al., 2015; Swanton et al., 2015; WHO, 2019). On the basis of 
this evidence, age has a major impact on cell mutations that lead to lung cancer (Adams 
et al., 2015; Wager et al., 2016). As age increases and exposure and degenerative 
processes accumulate, assessing age-related factors that contribute to lung cancer will 
help us understand the epidemiology of lung cancer (Wagner et al., 2016). The number of 
adults aged 65 or older is projected to reach 98 million by 2060 (Healthy People 2020, 
2019). As the population of older adults increases, morbidity and mortality from cancer 
will also increase (Healthy People 2020, 2019). Thus, identification of age-related factors 
contributing to lung carcinogenesis not only brings valuable information to the research 
community, but also explains why older populations are more vulnerable to lung cancer. 
It will also help support future preventive screening for early detection of lung cancer.  
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This chapter reviews findings from previous studies on the association between 
age-related factors and lung carcinogenesis. The results of this study add value to existing 
risk assessment standards and support future biomarker screening studies for early 
detection of cancers, as lung cancer symptoms appear only at an advanced stage. In 
addition, the findings from this dissertation underline the needs for further investigation 
of age-related factors and highlight knowledge gaps about causal variants and genetic 
factors responsible for the underlying demographic factors associations. The study also 
proposes short-term solutions to ensure further progress through a cross-sectional model.  
Literature Search Strategy  
The literature search used two libraries databases: the Walden University library 
database and the Stephen T. Tucker CDC library. Two search engines (PubMed and 
Scopus) were used to review scholarly articles that are relevant to this current study of 
age-related factors, using keywords with Microsoft Office 10. The keywords included 
lung cancer, stages, age, age at diagnosis, 5-year survival, and factors that contribute to 
lung cancer within the 5 years between 2015 and 2020. To elucidate the lack of 
understanding about age-related factors that contribute to lung cancer, a literature review 
is included to provide a summary of each finding. The statistical analyses answer the 
three research questions of this dissertation: (1) Is there a significant association between 
age at diagnosis and the stages of presentation of lung cancer? (2) Is there a significant 
association between the stage of lung cancer and demographic factors? (3) Is there any 
significant relationship between the stage of lung cancer, age at diagnosis, and 
demographic factors? The results from this dissertation provide additional information to 
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existing published research studies. Age-associated factors that contribute to lung cancer 
are understudied in the research community. However, in order to find the age-associated 
factors that contribute to lung cancer, this study uses age at diagnosis of lung cancer and 
the stages of lung cancer. Since there is little current research available to identify age as 
a marker for early detection of lung cancer, this study includes information about the 
proliferation of lung cancer, stages of lung cancer, factors that affect stages, and how age 
can be used as a potential marker for early detection of lung cancer.  
Lung Cancer  
Cancer is an abnormal proliferation of the cells in human tissues and organs and a 
type of disease caused by uncontrolled cell division (Toh et al., 2017). The leading cause 
of cancer deaths in the United States is lung cancer (Chu et al., 2018; Gingras, M., 2018; 
Mayo Clinic, 2019). Lung cancer is a type of cancer that starts when cells in the body 
begin to grow out of control in the lungs (ACS, 2019). The lung is the primary organ of 
the respiratory system, and the primary etiology of lung cancer is exposure to tobacco 
smoke (Bakulski et al., 2019; Chu et al., 2018; Dong et al., 2019; Ryan, 2018). Lung 
cancer is usually diagnosed at an advanced stage, and approximately 70% of patients are 
diagnosed with NCLS (Gyoba et al., 2016; Lozano et al., 2018). The overall survival rate 
for patients is approximately 15% at an advanced stage (AJCC, 2020). The two most 
common NSCLC are adenocarcinomas (~50%) and squamous cell carcinoma (~40%) 
(AJCC, 2010; Lozano et al., 2018). Patients with NSCLC are often diagnosed with an 
advanced stage of disease (Jin et al., 2018; Lozano et al., 2018). Adenocarcinomas start 
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in the cells that secrete substances such as mucus and occur mainly in both current and 
former smokers.  
Cancer Staging 
The cancer staging is based on three factors: tumor (T), node (N), and metastases 
(M). The staging system is maintained by the American Joint Committee on Cancer 
(AJCC) and the Union for International Cancer Control (UICC; ALA, 2020). The seventh 
edition of the TNM classification of lung cancer was published and implemented at the 
beginning of 2010, and the stages of lung cancer in this study were based on the seventh 
edition of the TNM classification. The primary sites of lung cancer are defined as 
carcinomas of the lung that arise from the alveolar, trachea, bronchi, visceral plural, the 
alveolar lining cells of the pulmonary parenchyma, or from the mucosa of the 
tracheobronchial tree (AJCC, 2010). The trachea (also known as windpipe) lies in the 
middle mediastinum, divides into the right and left main bronchi (the airways), and 
extends into the right and left lungs (AJCC, 2010). The bronchi then subdivide into the 
lobar bronchi in the upper, middle, and lower lobes on the right and upper and lower 
lobes on the left. The lungs are covered in membranes called the visceral pleura. The 
mediastinum contains structures in between the lungs, including the heart, thymus, great 
vessels, lymph nodes, and esophagus. From the great vessels of the primary site, the 
cancer cells travel through the aorta, superior vena cava, inferior vena cava, main 
pulmonary artery, and intrapericardial segments of the truck of the right and left 
pulmonary artery to the lymph nodes, and metastasize to different organs (AJCC, 2010).  
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The stages of lung cancer can be based on clinical (cTNM) and pathological 
(pTNM) staging. Clinical staging is a system that is based on cTNM, which is staging 
based on the evidence acquired before treatment, including physical examination, 
imaging studies, laboratory test, and staging procedures such as bronchoscopy or 
esophagoscopy with ultrasound directed biopsies (AJCC, 2010). Pathologic staging is 
another staging system that uses the evidence acquired before tested, supplemented or 
modified by the additional evidence acquired during and after surgery. The pathologic 
staging provides additional precise data used for estimating prognosis and calculating end 
results. According to the seventh edition of the TNM classification, approximately 50% 
of all NSCLC are localized or locally advanced at the time of diagnosis, and the rest of 
NSCLC are metastasized. In contrast, 80% of all SCLC are metastasized, and 20% SCLC 
are initially localized to the hemithorax and are usually locally advanced tumors (AJCC, 
2010).  
The staging describes the severity of individual cancer based on the extent of the 
original (primary) tumor size as well as the spread of cancer in the body (AJCC, 2010). 
The TNM staging system has traditionally been used for NSCLC, although it is supposed 
to be applied also to SCLC (AJCC, 2010). Understanding the stage of lung cancer based 
on the age at diagnosis will not only help health professionals to develop a prognosis and 
design a treatment plan for individual patients but will also inform vulnerable populations 
to get preventive screening as early as possible.  
According to the seventh edition of lung cancer classification, occult carcinoma 
stage (primary) tumors are tumors that cannot be identified and classified as Tx‒N0‒M0. 
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The letter T stands for tumor size and location of the original primary tumor. For example 
Tx (primary tumor cannot be evaluated), T0 (no evidence of primary tumor), Tis 
(carcinoma in situ―early cancer that has not spread to neighboring tissue), and T1‒T4 
(size and extent of the primary tumor) (AJCC, 2010). The letter T category describes 
tumor size, how deep the tumor has grown into the organ, and the extent of tumor growth 
into nearby tissues. For example, the two letters TX means the tumor cannot be 
measured, T0 means there is no evidence of a primary tumor, and Tis means in-situ or 
pre-cancerous cells are growing only in the most superficial layer of tissue without 
growing into deeper tissues. The numbers after T, N, and M (such as T1, T2, T3, T4:N1, 
N2, N3; and M1a, M1b) describe the tumor size and the amount of spread into nearby 
structures (ACS, 2019). The higher the number, the larger the tumor size, and the greater 
the extent of node and metastasis into nearby tissues. The stage T1 is ≤ 3 cm surrounded 
by lung/visceral pleura that has not involved the main bronchus. T1 has been 
subclassified into T1 (≤ 2 cm) and T1b (>2‒3 cm) in size. T2 has been subclassified into 
T2 (> 3‒ ≤ 5 cm) in size and involves the main bronchus without carina, regardless of the 
distance from carina, visceral pleural invasion, atelectasis or post abstractive pneumonitis 
extending to hilum (ACS, 2019). The T2a is >3‒5 cm in size, T2b is >5‒7 cm in size. T3 
is >7 cm in size and is the largest tumor that involves chest wall, pericardium, phrenic 
nerve, or satellite nodules in the same lobe (AJCC, 2010). T4 has multiple tumor nodules 
in the same lung, but a different lobe has been reclassified from M1 to T4.  
The tumor cells of each histological type release certain protein biomarkers into 
the bloodstream, which play an essential role in carcinogenesis (Zamay et al., 2017). 
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Tumor biomarkers are divided into (1) genetic, epigenetic, proteomic, metabolic, DNA 
and RNAs circulating in blood plasma, (2) exosomal microRNAs, (3) synthesis profile 
and level of miRNAs, (4) protein biomarkers, (5) circulating tumor cells, and (6) 
immune, stromal, and endothelial cells (Zamay et al., 2017). Biological materials such as 
tumor tissues, blood, exhaled breath condensate, sputum, and urine are generally used for 
non-invasive detection of LC biomarkers (Zamay et al., 2017). 
Lung cancer includes cancer cells in the lungs and also cancer cells that have 
spread to any lymph nodes. If the lung cancer is in the lungs and has not spread to lymph 
nodes, it can describe as stage 1. The lymph node is abbreviated as the letter (N), which 
can be considered as noncancerous (benign) or cancerous (malignant). When cancer cells 
break away from a tumor, they travel to other areas through bloodstream or the lymph 
system, and surviving cancer cells may end up in lymph nodes (ACS, n. d.). Normal 
lymph nodes are tiny and can be hard to find. However, when those lymph nodes are 
infected, inflamed, or cancerous, they can get large (ACS, n. d.). If there are a lot of 
cancer cells in a node, it can be seen easily as a large mass (ACS, n. d.). According to the 
Mayo Clinic, lymph nodes that are 30 millimeters or larger are more likely to be 
cancerous than smaller lymph nodes (Mayo Clinic, 2019). The risk of cancer diagnosis 
with a large-mass lymph node can depend on the age of an individual, because the 
mutation increases in cancer development as age increases. The chance that a lymph node 
becomes lung cancer is less than one percent for people younger than 35 years (Mayo 
Clinic, 2019). Cancer can appear in the lymph nodes in two ways: it can either start there 
at the organ or it can spread there from somewhere else (ACS, 2019). The letter NX 
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means cancer cells in the nearby lymph nodes cannot be evaluated, and N0 means nearby 
lymph nodes do not contain cancer cells. The numerical numbers after the letter N (N1, 
N2, and N3) describe the size, location, and number of nearby lymph nodes affected by 
cancer. Stage N1 means ipsilateral peribronchial or hilar nodes and intrapulmonary nodes 
(ACS, 2019). Stage N2 means ipsilateral mediastinal and subcarinal nodes.  
Stage N3 is contralateral mediastinal or hilar. The letter N stands for nodes that 
tell whether cancer has spread to the nearby lymph nodes (AJCC, 2010): for example, N0 
(no regional lymph node involvement―no cancer found in the lymph nodes), and N1‒N3 
(involvement of regional lymph nodes―number and extent of spread). It is important to 
know whether the lung cancer has spread to the lymph nodes around the lung to diagnose 
the stages of cancer. Regional lymph nodes are the sites where lymph nodes extend from 
the supraclavicular region to the diaphragm. During the past three decades, two different 
lymph maps have been used to describe the regional lymph nodes potentially involved in 
lung cancers (AJCC, 2010). The first lymph map was proposed by the late professor Dr. 
Tsuguo Naruke to Japanese officials and is used primarily in the Japan Lung Cancer 
Society (AJCC, 2010). The second lymph map was proposed by the Mountain-Dresler 
modification of the American Thoracic Society lymph node map and is used primarily in 
North American and Europe (AJCC, 2010). However, some locations of lymph nodes 
differ between the two maps, especially in nodes located in the paratracheal, 
tracheobronchial angle, and subcarinal areas (AJCC, 2010). To reconcile the 
discrepancies between the two maps, the International Association for the Study of Lung 
Cancer (IASLS) proposed a new lymph node map that provides more detailed 
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terminology for the anatomical boundaries of lymph node stations (AJCC, 2010). The 
latest new lymph node map proposed by IASLS is now the means of describing regional 
lymph node involvement for lung cancers (AJCC, 2010). However, the use of lymph 
node zones for N staging remains investigational and needs to be confirmed by future 
prospective studies.   
The letter M category describes whether cancer has metastasized to distant parts 
of the body (ACS, 2019). According to the AJCC 7th edition, metastases are found in 
most pleural effusions and are due to the size of the tumor (AJCC, 2010). Lung 
metastasis is a cancerous growth in the lung that has spread from its primary site to other 
places in the body (ALA, 2020; Schueller & Herold, 2003). For example, stage M0 
indicates no distant metastatic, i.e., cancer has not spread to other parts of the body. The 
stage M1 indicates that distant metastases were found and subdivided into M1a and M1b. 
M1a has been reclassified as malignant pleural, pericardial effusions, and separate tumor 
nodules in the contralateral lungs. In addition, nodules that are found in the contralateral 
lung are also classified as M1a. M1a includes malignant pleural effusion with a median 
overall survival of eight months in 448 patients and contralateral lung nodes that had an 
overall survival of ten months in 362 patients. M1b classified as distant metastases in 




Factors That Can Affect the Stage of Cancer  
The values of T, N, M are not the only criteria that can determine the stage of 
lung cancer, but other factors such as grade, cell type, tumor location, tumor markers 
level, performance status, patient age, and gender (AJCC, 2010). 
Grade 
In general, for most cancers, the grade is measured by the abnormality based on 
the appearance of the cancer cells (AJCC, 2010). The cancer grade is usually assigned a 
number on a scale of 1‒3, with the larger number being the highest grade or 
undifferentiated cancer. Low-grade (well differentiated) cancers are characterized by 
cells that look largely the same as cells from normal tissue. High-grade or poorly 
differentiated cancers are characterized by cancer cells which look very different from 
normal cells.  
Cell Type 
 Some cancers can be made up of different types of cells and it can affect 
treatment and outlook (ACS, 2019). Therefore, it can be used as a factor of staging. There 
are eight types of lung cells: [(i) alveolar type 1 cells [8%], (ii) alveolar type 2 cells 
[16%], (iii) capillary endothelial cells [30%], (iv) pneumocytes type 1 (v) pneumocytes 
type 2 (vi) alveolar macrophage, (vii) alveolar ducts, and (viii) bronchioles] (Crapo et al., 
1982). Although some molecular abnormalities of cells are used to stratify patients for 
treatment, none of these cells are being used for lung cancer staging (AJCC, 2010).  The 
tumor location is another factor of staging because it affects the prognosis of cancer.  
Lungs are two spongy organs located on each side of the chest that take in oxygen during 
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inhalation and release carbon dioxide during exhalation (Mayo Clinic, 2019). The right 
lung is shorter and wider than the left lung. The right lung consists of three lobes (upper, 
middle, and lower) and the left lung consists of two lobes (upper and lower). For 
example, the stage of lung cancer can depend on the lobe—whether the cancer is in the 
upper, the middle or lower third of the lungs, or overlapping lesion of the lung.  
Smoking 
Lung cancer is caused by both internal and external risk factors (NCI, n. d.). 
Internal factors are things that cannot be controlled such as age, sex, and family history. 
However, external factors such as cigarette smoking and exposure to carcinogens can be 
controlled. Having several risk factors can make a person more likely to develop lung 
cancer, such as an older person who continues to smoke cigarettes. The longer a person 
smokes, the greater the risk of lung cancer (ACS, 2019). Although age cannot be 
controlled, age-related risk factors can be controlled, such as reducing an avoidable 
exposure to carcinogens such as changing a lifestyle by cessation of smoking to delay the 
development of cancer. In 2019, the estimated number of new cases of lung and bronchus 
cancer were 228,150 and of these new cases, 62.5% were predicted to die (NCI, n.d.). 
The number of new cases and the percentage of predicted deaths have not significantly 
decreased over the past years, and lung cancer is still lethal both nationally and 
internationally.  
The main function of the lungs is to deliver and convert air to oxygen from the 
airway through pulmonary ventilation to the bloodstream (Mayo Clinic, 2019). However, 
inhalation of carcinogens from cigarette smoke that travels through the pulmonary 
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ventilation to the bloodstream attack normal healthy cells and change their chemical 
compounds that lead to cell mutations (Bakulski, Dou, Lin, Long & Colacino, 2019). 
Pulmonary ventilation provides air to the alveoli for gas exchange and delivers oxygen to 
the bloodstream during inhalation and eliminates carbon dioxide from the lungs during 
exhalation (Mayo Clinic, 2019). However, when the lungs receive carcinogens through 
contaminated air from the pulmonary ventilation, the alveolar-capillary membrane carries 
out carcinogen-contaminated oxygen molecules to the bloodstream and returns 
carcinogen-contaminated carbon dioxide molecules to the lungs. Elderly populations are 
vulnerable to lung cancer, and it is a public health problem, especially when the aging 
population is growing and life expectancy is increasing in the United States (Battle, 
2007).  
According to the Centers for Disease Control and Prevention (CDC), people who 
smoke cigarettes are 15‒30 times more likely to get lung cancer or die from lung cancer 
than those who do not smoke (CDC, 2019). Cigarettes contain at least 69 carcinogens that 
promote cancer in humans (Kathuria, Gesthalter, Spira, Brody, & Steiling, 2014; Izzotti 
et al., 2016; National Toxicology Program, 2016; Pu, Xu, Zhang, Yuan, Hu, Huang, & 
Wang, 2017). Nicotine, one of the carcinogens in cigarettes, is addictive to the brain 
(Battel, 2007). Because of the unpleasant side effects of smoking cessation, many people 
are unwilling to stop smoking. However, the good news is that since alternative methods 
are available to replace cigarette smoking and may reduce the desire to smoke cigarette. 
These alternative methods such as the nicotine patch and e-cigarettes are available to stop 
smoking, but studies have found that nicotine patch and e-cigarettes contain harmful 
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chemicals such as formaldehyde and may serve as delivery agents that deposit deeply in 
the lungs and are known to cause lung damage (Salamanca et al., 2018). Formaldehyde is 
absorbed from the nose to the upper part of the lungs. Repeated exposure to 
formaldehyde vapors at 40 ppm, 6 hours/day, 5 days/week for up to 13 weeks produced 
80% mortality in an animal study with mice (ATSDR, 1999). Thus, cessation of cigarette 
smoking is the only effective way to reduce the rate of mortality and morbidity caused by 
lung cancer (Akushevich, Kravchenko, Yashkin & Yashin, 2018).  Cigarette smoking is 
one major risk factor for lung cancer, and cigarettes contains at least 250 known harmful 
substances. Of these substances, at least 69 of them are carcinogens that are linked to 
lung cancer (National Toxicology Program, 2016). The longer an individual smoke 
cigarette, the more carcinogens accumulate in the lungs. Carcinogen-contaminated 
oxygen is then released into the blood stream (Bakulski et al., 2019; Dong et al., 2019).  
Age 
Despite medical advances, screening for early detection of lung cancer is failing 
because of a lack of knowledge about how age-related factors contribute to lung 
carcinogenesis and insufficient knowledge of how fast cancer grows and spreads. For 
example, lung cancer is already at a late stage when cancer tissue on a computed 
tomography (CT) scan is found (Zamay et al. (2017). The quantification of cancer cells’ 
growth rate can be determined by doubling time (DT) (Mehrara, Forssell-Aronsson, 
Ahlman, Bernhardt, 2007). The cancer cells’ growth rate is based on doubling-time 
(Mehrara, Forssell-Aronsson, Ahlman, Bernhardt, 2007). The rate of growth in the size of 
the lung nodules is much faster for malignant than for benign nodules (Harris et al., 
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2012).  Aria et al. (1994) reported that rapidly growing tumors tend to have a poorer 
prognosis than slowly growing tumors. Although the elderly population is more sensitive 
to carcinogens because of the lower physiological reserve capacity and slower immune 
system response, it is unclear whether elderly populations are more likely than younger 
populations to have rapidly growing tumor doubling time (Fougère et al., 2018). These 
cells get instruction from a gene in the DNA of a molecule to make a protein that is 
essential for life and used by the cell to perform certain functions: whether to grow or to 
survive and perform a different job to help lung function. These cells contain genes that 
are a portion of DNA (deoxyribonucleic acid). DNA carries genes (genetic information), 
and changes in key genes cause the cells to be in disorder, such as developing cancer 
(Crapo et al., 1982; Shao et al., 2018). Increasing knowledge in the association of how 
different age-related factors contribute to the growth of different types of lung cancer 
cells will help us understand the biology of lung cancer. 
Age Differences in Cancer 
Studies found lung cancer is the leading cause of cancer death between ages 60 
and 79, and 80%‒85% of them were caused by NSCLC (ACS, 2019; Jin et al., 2018; 
Fougère et al., 2018). Age could be the primary risk factor for major human pathology, as 
aging is the time-dependent physiological functional decline that affects most living 
organisms. It affects mutations and is the most profound risk factor for many non-
communicable diseases such as cancer (Xia et al., 2017). In order to determine the 
association between age and molecular biomarkers, the American Federal of Aging 
Research (AFAR) proposed criteria for biomarkers of aging (1) it must predict the rate of 
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aging, (2) it must monitor a basic process that underlines the aging process, not the 
effects of the disease, (3) it must be able to be tested repeatedly without harming the 
person, and (4) it must be something that works in humans and in laboratory animals 
(AFAR, n. d.). The molecular biological materials should predict the rate of aging and 
must monitor a basic process that underlies the aging process. According to the National 
Cancer Institute, approximately 82% of new lung cancer diagnoses are in people aged 55 
to 84. The average age at the time of diagnosis is approximately 70 years old (NCI, n. d.). 
Although the health effects of carcinogens affect all age groups, the elderly population is 
more sensitive to exposure to carcinogens (Fougère et al., 2018). As aging causes a 
biological system to decline, assessing age-related lung cancer helps explain that aging is 
one of the risk factors that influence the development of early cellular epigenetic 
alterations involved in carcinogenesis (Jin et al., 2018; Xia & Han, 2018). Cancer occurs 
when cells have multiple mutations; 90% of cancers are caused by mutations; and the 
incidence of cancer increases as age increases (Griffith et al., 2000, ACA, 2015; 
Hammond, 2015; Adams et al., 2015; Swanton et al., 2015; WHO, 2019). The aging 
population is growing, and more than 70% of cancer-related deaths occur in the elderly 
population (Fougère et al., 2018; McClelland et al., 2016). Increasing knowledge of the 
causation of lung cancer, assessing factors affecting the biological initiation, and 
progression of the disease will bring positive social changes to our society.  
Screening 
Because of the age threshold of lung cancer begins at 65‒74, the current lung 
cancer screening targets individuals beginning at age 55 (Annangi et al., 2019). As the 
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incidence of cancers and diseases increases with age (White, 2014; Yang et al., 2018), 
age could be a valuable tool to measure physiological age, assess healthy aging, and 
predict risk factor of cancers and diseases (AFAR, n. d.; McClelland et al., 2017). Our 
cells become less efficient with age at performing normal functions (Wagner et al., 2016), 
and age-associated factors such as the decline of immune function may lead to increased 
cancer incidence (Chen et al., 2019). For example, the accumulation of degradative 
processes that are reinforced by multiple alterations and damage within molecular 
pathways can weaken the immune system and make a person less able to defend against 
infection and disease (Wagner et al., 2016). Yang et al. (2018) found and association 
between circular RNA (cRNA) in aging and the cRNA in diseases such as cancer.  
Biomarkers 
Based on the AFAR criteria, Xia et al. (2018) investigated biomarkers of aging 
using telomeres, DNA repair, epigenetic modifications, transcriptome profiles, non-
coding RNAs, metabolism, protein metabolism, lipid metabolism, oxidation stress, and 
mitochondria (Xia et al., 2017). Xia et al. (2017) found that telomeres are 
ribonucleoprotein complexes at the end of chromosomes and become shorter after each 
replication. The enzymes are responsible for its replication and shortness of telomeres. 
Thus, the length of telomeres in leukocytes has been associated with aging and life span 
as well as age-related diseases such as cardiovascular diseases, cancer, and neurological 
disorder (Xia et al., 2017). Aging has implications for the link between DNA damage and 
repair because of the accumulation of senescent cells or genomic rearrangements (Xia et 
al., 2017). The age-related changes in DNA methylation patterns are measured by the 
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epigenetic clock among the best-studied aging biomarkers (Xia et al., 2017). Researchers 
found that cell-to-cell expression variation (measured by single-cell RNA seq of high-
dimensional flow cytometry sorted T cells) is associated with aging and disease 
susceptibility (Xia et al., 2017).  
Metabolism 
MicroRNAs (miRNAs) are small non-coding RNAs that regulate a broad range of 
biological process, including metabolism and aging (Xia et al., 2017). Among the 
miRNAs, circulating miRNA (c-miRNA) are stable in plasma. The miR‒34a was the first 
miRNA with an altered expression pattern during mouse aging. The expression has been 
found to correlate with age-related hearing loss in mice and humans (Xia et al., 2019). 
Thus, the association between age and DNA methylation can be extended to study age-
related diseases. RNA-seq, non-coding RNAs are a broad range of biological processes 
including metabolism and aging (Xia et al., 2017). In protein metabolism, protein 
carbamylation is one of the non-enzymatic post-translational modifications that occur 
throughout the whole life span of an organism. The tissue accumulation of carbamylation 
in proteins increases as age increases and is believed to be a hallmark of molecular aging 
age-related disease (Xia et al., 2017). In lipid metabolism, triglycerides are found to 
increase monotonously with age, and phophosphingolipids in serum sample are found as 
a putative marker of healthy aging (Xia et al., 2017).  
Oxidative Stress 
Oxidative stress and mitochondrial dysfunction have been a class of aging marker 
as the products of oxidative damage to proteins include 0-tyrosine, 3-chlorotrosin, and 3-
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nitrotyrosin. Oxidative stress is an imbalance of free radicals and mainly produced in 
mitochondria. Dysfunctional mitochondria can contribute to aging independently of 
reactive oxygen species. As age is a biological process of life that spans from birth to 
death (Xia et al., 2017); physiological functional can decline as age increases. Yang et al. 
(2018) stated that the specific cRNAs were identified in many cancers, including lung 
cancer (NSCLC), and these cRNAs are associated with age as well as diseases (Yang et 
al., 2018). However, individuals of the same age may not age at the same rate (Xia et al., 
2017). For example, some people who reach 85 years old are in good physical and mental 
health while others may have difficulties (AFAR, n. d.).  
DNA Methylation 
Although the link between the age of individual and cancer is complex, 
researchers found some age-associated epigenetic modifications such as the decrease in 
DNA methylation and an increase in promoter-specific CpG islands methylation are also 
features of cancer (Fougère et al., 2018). In order to determine whether there is any 
influence of age on the cell biological methylation profile altered during tumorigenesis, 
Fougère et al. (2018) investigated the association between P16 gene expression (protein 
inhibitors that are often silenced during carcinogenesis) and promoter-specific CpG 
islands methylation. Fougère et al. (2018) found that P16 significantly increases with age, 
and DNA methylation significantly decreases with age after exposure to PM (Fougère et 
al., 2018).  
In the DNA methylation study, only three CpG sites could predict age with a 
mean absolute deviation from the chronological age of less than 5 years (Xia & Han, 
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2018). The elderly population experiences a complex relationship with the environment, 
since they are more vulnerable to carcinogens because of a lower physiological reserve 
capacity, a slower response to the immune system, and less ability to tolerate stress 
(Fougère et al., 2018). The degenerative pathologies such as cancer are directly caused by 
genetic modifications that are also found in the biology of aging (Fougère et al., 2017). In 
a DNA methylation study, Bakulski et al. (2019) found that exposure to cigarette smoke 
is associated with altered DNA methylation throughout the genome. The abnormal 
growths of cells can transform into cancer cells in any part of the human body and result 
in malignant tumor formation in the organs (Shao et al., 2018). Cell proliferation is 
another factor that contributes to carcinogenesis. It is an essential process of normal 
tissue development that results in an increasing number of cells. It is defined by the 
balance between cell divisions and cell loss through cell death or differentiation 
(Yokoyama et al., 2019). However, aberrations in cell proliferation can give rise to 
malignant transformation and cancer pathology (Jone & Baylin, 2007; Yokoyama et al., 
2019). The main difference between a mutagen and carcinogen is that a mutagen causes a 
heritable change in the genetic information, whereas a carcinogen causes or promotes 
cancer in humans (Griffiths et al., 2002).   
Biomarkers 
Millions of human cells in a human body are linked to age as the properties of 
chemistry change with aging (Zagryazhskaya & Zhivotovsky, 2014). Yet, previous 
biology research studies found aging-related biomarkers in the gene, molecule, and 
protein that can also be found in biological materials such as telomeres, proteomics, 
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cytokines, etc. (Bai, 2018; Hayashi, 2017; Xia & Han, 2018). More than 90% of tumor 
cells were associated with telomerase activity. Shortening in telomere is caused by a 
mutation that is linked to an increased risk of aging-related diseases and morality 
(Hayashi, 2017, Shao et al., 2018).  As numerous degenerative pathologies such as 
cancers and diseases are directly caused by mutations in cells, DNA methylation and cell 
proliferation (Fougère et al., 2018) could be more representative of an individual’s health 
status than chronological age (Bai, 2018). 
According to the American Federation for Aging Research, in order to use the age 
of an individual as a predictor of ill health, the markers have to meet four criteria: (1) can 
predict the rate of aging, (2) can monitor the basic process that underlies the aging 
process, (3) can be tested repeatedly without harming the person, and (4) can work with 
human and laboratory animals (Bai, 2018). As age is one of the essential variables in 
many public health research studies, studies on aging can be reproduced and may be well 
suited for prospective studies involving larger cohorts, which have a potential major 
advantage for public health. Using age-related biomarkers in research studies has 
advantages because they are stable, reliable, and can be measured in a variety of 
biological specimens (Sun et al., 2018).  
Although people of the same age may not age at the same rate (White, 2014), 
aging markers can be a valuable tool to measure physiological age to assess how the 
biology of aging affects lung carcinogenesis. However, not all human organs react to 
exposure to carcinogens the same way, since different organs have different functions 
(Popović et al., 2018). For example, lungs are exposed to carcinogens through the 
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inhalation of carcinogen-contaminated air, while skin is exposed to a radiated carcinogen 
through direct contact with the sun. Thus, age-related risk factors that contribute to lung 
cancer may be a valuable tool for measuring the dose of exposure to carcinogens over a 
period that an individual is exposed to carcinogens. 
Mutagenesis 
In general, carcinogenesis needs at least six or seven mutagenic events (over a 
period of 20‒40 years), which can be described in three different steps: initiation, 
promotion, progression (Battle, 2009; Weiss, 2004). As carcinogenesis can take years to 
develop into cancer, cancer prevention can begin as early as in utero (Battle, 2009). In the 
investigation of molecular biomarker screening for early detection of lung cancer using 
positive predictive value (PPV), researchers found that circulating miRNA profiles of 
lung cancer are stable in blood and strongly affected by age, gender, smoking status 
(Ameling et al., 2015; Atwater & Massion, 2016; Sun et al., 2018; Zagryazhskaya & 
Zhivotovsky, 2014).  For example, Zagryazhskaya & Zhivotovsky (2014) found that 
miRNAs play an important role in cancer cell development and altered in lung cancer 
cells during aging.  
Dong, Zhang, He, Lai, Alolga, Shen…Christiani (2019) performed integrative 
analyses of clinical information, DNA methylation, and gene expression data using 825 
lung cancer patients with early-stage cancer (stage 1 and II) from five cohorts. They 
focused on developing prognostic models with trans-omic biomarkers for early-stage 
lung adenocarcinoma (LUAD). They used the iCluster plus machine learning approach 
with a joint latent variable model for fusing clinical variables that includes two age 
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groups: age < 65 and age ≥ 65 (based on the definition of elderly using United Nation 
standard) and trans-omic biomarkers (12 DNA methylation and 7 gene expression 
probes)., Dong et al. (2019) found that trans-omic biomarkers have different prediction 
ability, significant heterogeneity, and diverse effects on early-stage lung adenocarcinoma 
prognosis. The miR‒346 expression was upregulated in NSCLC patients with elder age, 
bigger tumor sizes, smokers, positive lymph node metastasis, and advanced stage. Each 
of these variables is assumed to be a predictor of overall survival in NSCLC patients 
(Dong et al., 2019).  In the lung cancer cohort study of Haung et al. (2019), the median 
age at lung cancer diagnosis was 69.8 (range between (53.6‒82.0) using circulating 
markers of cellular immune activation as biomarkers for immune regulation in a pre-
diagnostic blood sample (Haung et al., 2019). 
Studies found age-associated increases in the initiation and progression of the 
mutant stem and progenitor clones. This age-associated increase in the initiation and 
progression of the mutant stem and progenitor highlights the roles of stem cell 
quiescence, replication-associated DNA damage, telomere shortening, epigenetic 
alterations, and metabolic challenges as determinants of stem cell mutations and clonal 
dominance in aging (Adams et al., 2015). A gene mutation is a permanent alteration in 
the DNA sequence that can further be classified into hereditary mutations and acquired 
(somatic) mutations that can occur at some time during the life of individuals (Jin et al., 
2018). Cancer is thought to include gene mutations, and mutation is an inevitable 
consequence of normal aging that depends in part on lifestyle (Yokoyama et al., 2019). A 
decrease in genome integrity and impaired organ maintenance increases the risk of cancer 
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development (Adams et al., 2015). In the study of age-related remodeling of oesophageal 
epithelia by mutated cancer drivers, Yokoyama et al. (2019) found that somatic mutations 
were detected in 96% of physiologically normal oesophageal epithelia (PNE) tissues. 
Accumulated errors in signaling the cell, and abnormalities that can cause the cell to stop 
its normal function are associated with cancer (Jin et al., 2018; Mayo, 2017).   
Chemical Carcinogens 
This section focuses on one of the three main cancer-causing agents that can 
cause mutations to the cell. When this cancer-causing agent (chemical carcinogen) enters 
our bodies through ingestion or inhalation, it often results in the activation of a compound 
to reactive state (Battle, 2009). The reactive molecules are capable of damaging DNA 
and can lead to mutations that contribute to carcinogenesis (Battle, 2009). The good news 
is that somatic mutations that are caused by lifestyle behavior, occupational exposure, 
and environmental exposure cannot be passed on to the next generation (Genetics Home 
Reference, 2019). 
Mutations in the cell genome lead to proteins changes in the body that regulate 
cell growth and are caused by carcinogens (Adams et al., 2015; Yokoyama et al., 2019). 
Studies have found that at least 90% of carcinogens are mutagens, and these cell 
mutations increase as age increases (Adams et al., 2015; Enge et al., 2018; Smith et al., 
2009; Swanton et al., 2015; Weiss, 2002; Yancik et al., 2005). According to Enge et al. 
(2018), as organisms age, cells accumulate genetic and epigenetic error that leads to 
cancer cell development. Mutations can be subtyped into gene mutations, constitutional 
mutations, somatic mutations, chromosomal aberrations, structural abnormalities, and 
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numerical abnormalities (Jones & Baylin, 2002; Shao et al., 2018). Mutations can 
increase in number and size with aging and ultimately replace almost the entire 
epithelium in the elderly patients (Yokoyama et al., 2019). Although cancer affects 
anyone and almost any part of the body, elderly individuals with high risk exhibited a 
higher mutation density (NCI, n. d., Yokoyama et al., 2019).  
Gender Differences  
According to The Cancer Atlas, lung cancer is the leading cause of cancer death 
among men in over half of the world (The Cancer Atlas, 2018).  Research studies show 
the evidence of gender differences: lung cancer affects more men than women, and 
women patients have better survival rates at every stage of the disease (Xiao et al., 2016). 
In contrast, a join-point analysis study Siroglavić et al. (2017) found an increased 
incidence rate in women and a decreased incidence rate in men in Croatia. The gender 
differences in mutation burden might be the reason why there is a clinical gender 
difference in the outcome of lung cancer cases (Xiao et al., 2016). The highest death rates 
and shortest survival times in most cancers are found in African American men 
(McClelland et al., 2017). In the study of Genome-wide association (GWAS), Bossé et al. 
(2019) identified genetic factors robustly associated with lung cancer and stated that 
some genetic risk loci have refined to more homogeneous subgroups of lung cancer 
patients such as histological subtypes, smoking status, gender, and ethnicity. 
Racial and Ethnicity Differences 
Cancer outcomes vary among different racial and ethnic groups. Racial and ethnic 
disparities exist in cancer incidence and survival (Stram et al., 2019; Robbine et al., 
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2015). For example, in the United States, African Americans have a higher rate of 
mortality than Whites for most common cancers and cancer overall (Stram et al., 2019; 
Robbins et al., 2015). Stram et al. (2019) stated that the differences were more evident at 
relatively low levels of smoking intensity (fewer than 20 cigarettes per day) than at 
higher intensity. In the overall risk study of lung cancer and lung cancer subtypes, Stram 
et al. (2019) found that African American and Native Hawaiians men had higher 
incidences of lung cancer than Japanese Americans and Whites (Stram et al., 2019). 
White men (40%), Japanese American men (54%), and Latino men (70%) had lower 
excess relative risk (ERR) of lung cancer for the same quantity of cigarettes smoked 
(Stram et al., 2019). The risk of NSCLC with adenocarcinoma and squamous cell 
carcinomas was highest in African Americans, while the risk of small cell lung cancer 
was highest in Native Hawaiians (Stram et al., 2019). The potential reasons why African 
Americans are more susceptible to NSCLC include that they are less likely to receive 
interventional care (McClelland et al., 2017), are more likely to live in working-class 
communities (Ryan, 2018), are at increased risk for exposure to environmental hazards 
(Ryan, 2018), and have genetic factors that make them more susceptible to the effects of 
carcinogens of chemical exposure (Ryan, 2018). Several studies show that African 
Americans are typically diagnosed with lung cancer at earlier ages compared with Whites 
and other races (Robbin et al., 2015; Ryan, 2018). Using SEER Medicaid and Medicare 
data, McClelland et al. (2016) found that African Americans are 42% less likely than 
Whites to receive radiation therapy, which could be because African American men fear 




There are striking geographic differences in the rate of morbidity and mortality 
caused by lung cancer in different geographic regions. The national diversity reflects both 
the presence of local risk factors for lung cancer and the extent to which effective lung 
cancer control measures have been implemented. Much of the observed variation in 
recorded lung cancer cases in different registry populations can be attributed to lifestyle, 
occupational exposure, and environmental factors. The American Lung Association 
collected incidence, survival rates, stages of diagnosis, surgical treatment, and availability 
of screening centers. According to the state data of the American Lung Association 
(ALA, 2020), the national incidence rate of lung cancer is 59.6 per 100,000, and the 5-
year survival rate is 21.7%. In Kentucky, the rate of new lung cancer cases is 92.6 per 
100,000 which is significantly higher than the national rate of 59.6 per 100,000. The 5-
year survival rate in Kentucky is 17.6%, which is significantly lower than the national 
rate of 21.7% (ALA, 2020). In Louisiana, the rate of new lung cancer cases is 67.9 per 
100,000 which is significantly higher than the national rate of 59.6 per 100,000. The 5-
year survival rate is 17.0% which is lower than the national rate of 21.7% (ALA, 2020). 
In Michigan, the rate of new lung cancer cases is 64.5 per 100,000 which is significantly 
higher than the national rate of 59.6 per 100,000. The 5-year survival rate is 23.2% which 
is higher than the national rate of 21.7% (ALA, 2020). In Georgia, the rate of new lung 
cancer cases is 64.5 per 100,000, which is significantly higher than the national rate of 
59.6 per 100,000. The 5-year survival rate is 19.3%, which is lower than the national rate 
of 21.7% (ALA, 2020). In Iowa, the rate of new lung cancer cases is 63.5 per 100,000 
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which is significantly higher than the national rate of 59.6 per 100,000. The 5-year 
survival rate is 19.1% which is lower than the national rate of 21.7% (ALA, 2020).  
In Connecticut, the rate of new lung cancer cases is 60.2 per 100,000 which is not 
significantly different from the national rate of 59.6 per 100,000. The 5-year survival rate 
is 26.4%, which is significantly higher than the national rate of 21.7% (ALA, 2020). In 
Utah, the rate of new lung cancer cases is 59.6 per 100,000 which is significantly lower 
than the national rate of 59.6 per 100,000. The 5-year survival rate is 21.4% which is not 
significantly different than the national rate of 21.7% (ALA, 2020). In New Jersey, the 
rate of new lung cancer cases is 56.6 per 100,000 which is significantly lower than the 
national rate of 59.6 per 100,000. The 5-year survival rate is 25.0% which is higher than 
the national rate of 21.7% (ALA, 2020). 
In Alaska, the rate of new lung cancer cases is 56.3 per 100,000, which is lower 
than the national rate of 59.6 per 100,000. The 5-year survival rate is 17.6%, which is 
significantly lower than the national rate of 21.7%. In Hawaii, the rate of new lung cancer 
cases is 46.0 per 100,000, which is lower than the national rate of 59.6 per 100,000. The 
survival rate is 18.7%, which is lower than the national rate of 21.7%. In New Mexico, 
the rate of new lung cancer cases is 39.9 per 100,000 which is significantly lower than the 
national rate of 59.6 per 100,000. The 5-year survival rate for New Mexico is 19.6% 
which is lower than the national rate of 21.7% (ALA, 2020). In California, the rate of 
new lung cancer cases is 42.3 per 100,000, which is significantly lower than the national 
rate of 59.6 per 100,000. The survival rate of 21.7% not significantly different than the 




Carcinogenesis, also known as cancer development, is a multistage process that 
can be prevented from progressing to subsequent stages (Battle, 2009; Jin et al., 2018). A 
cancer stem cell is small and has the capacity to generate the different cell types that 
constitute the whole tumor (Toh et al., 2017) that can invade adjoining parts of the body 
(Adams et al., 2015; Griffith et al., 2000, ACA, 2015; Hammond, 2015; Swanton et al., 
2015; WHO, 2019). Normal cells can divide in the process of mitosis, repair themselves, 
differentiate, or die under the control of the molecular mechanism (Tyson & Novak, 
2014). However, when epigenetic changes occur, such as DNA methylation and histone 
modifications, the normal cell may transform into cancer stem cells (Toh et al., 2017). 
The main difference between a mutagen and carcinogen is that the mutagen causes a 
heritable change in the genetic information, whereas a carcinogen causes or promotes 
cancer in humans. Carcinogenesis is the mechanism by which tumors occur because of 
mutagenic events. In general, carcinogenesis needs at least six or seven mutagenic events 
over a period of 20‒40 years, which can be described in four different steps:  
1. Initiation: cells change genetic material 
2. Promotion: promoters increase the proliferation of cells 
3. Malignant transformation: cells acquire the properties of cancer 
4. Tumor progression: the last phase of tumor development (Roberti et al., 
2019).  
Jia et al. (2016) found that the expression level of miRNA in the plasma of 
(NSCLC) and (SCLC) was lower than in the control group and that the occurrence and 
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prognosis of lung cancer may be related to the expression quantity of miRNA (Jia et al., 
2016). These biomarkers are up-regulated amongst lung cancer patients. As cited in 
Gingras (2018), although differences in biomarkers of miRNA‒486 and miRNA‒499 
expression can be analyzed (Jia, Zang, Feng, Li, Zhang, Li, Wang, Wei, & Huo 2016), Jia 
et al. (2016) found no statistical significance between gender, age, history of smoking, 
pathologic types, differentiation types, and primary tumor extent and the expression of 
miRNA‒486.  
Cancer causes mutations in the cell genome, leading to the changes in the proteins 
that regulate cell growth. These changes are caused by changes to the DNA mutations in 
the cells (Shao et al., 2017). During cancer development, five biological capabilities are 
acquired: (1) mutations, (2) conquering the barriers of cell death, (3) sustaining 
proliferative signaling, (4) resistant to cell death, and (5) activation of the mechanism for 
invasion and metastatic to the other part of the body (Shao et al., 2017). Homeostasis 
maintains a balance between cell proliferation and cell death (Shao et al., 2017). 
However, when destruction occurs in homeostasis, it leads to the uncontrolled growth of 
cells and causes the loss of a cell’s ability to undergo apoptosis, resulting in a genetic 
error to the DNA cycle that could develop the process of cancer (Shao et al., 2017). A 
gene mutation affects the cell in many ways, and some mutations stop a protein from 
being made. Others may change the protein that is made so that it will no longer work the 
way it should, which leads to cancer (American Cancer Society, 2018; Shao et al., 2017).  
Cancer is a genetic disease and is caused by mutations to genes in the 
deoxyribonucleic acid (DNA) (NCI, 2017) Each of those individual genes signal the cell 
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activities to perform, to grow, or to divide (Mayo, 2017). The three main classes of 
agents causing cancer are chemicals, radiation, and viruses (Choudhuri, Chanderbhan, & 
Mattia, 2018). At least one of these exposures causes the normal cells to become 
abnormal, which leads to the development of cancer (Choudhuri, Chanderbhan, & Mattia, 
2018). Cancer arises from almost anywhere in the human body from the accumulation of 
genetic mutations, or when the orderly process breaks down to cause the old or damaged 
cells to survive instead of forming a new cell. These extra old and damaged cells can 
replicate without stopping and may form tumors (NCI, n.d.). As cells can react to their 
direct microenvironment, cancer can also develop in complex tissue environments, which 
they depend on for sustained growth, invasion, and metastasis (Quail & Joyce, 2013). In 
the past few decades, the impetus for studies of biological materials has grown stronger 
in public health after the findings of markers in cancer cells. Since carcinogenesis begins 
at the cell levels, the biomarkers could measure genetic risk, which is caused mostly by 
cell mutations.  
Atwater and Massion (2016) and Chu, Lazare, and Sullivan (2018) assessed 
whether molecular biomarkers can be used for screening programs to reduce the costs of 
screening and to reduce the number of individuals harmed by screening. To assess the 
risk, Atwater and Massion (2016) investigated biomarkers such as serum-based 
inflammation, circulating miRNA, and a strong positive predictive value with great 
specificity or negative predictive value with greater sensitivity. Atwater and Mission 
(2016) found that serum-based and circulating miRNA profiles are associated with 
inflammation marker levels and are stable in the blood. They can be used as biomarkers 
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of disease and may be a benefit for future study of predictive biomarkers of disease 
(Atwater & Masson, 2016). Chu, Lazare, and Sullivan (2018), Jia et al. (2016), Pu et al. 
(2017), Shen et al. (2011), Yang et al. (2015), Xing et al. (2018), Zagryazhskaya and 
Zhivotovsky (2014) investigated how to improve the accuracy of lung cancer screening to 
decrease over-diagnosis and morbidity by using blood and serum-based biological 
materials (Gingras, 2018). These researchers found that miRNA biomarkers are 
promising markers for early detection of lung cancer (Chu et al., 2018; Jia et al., 2016; Pu 
et al., 2017; Shen et al., 2011; Yang et al., 2015; Xing et al., 2018; Zagryazhskaya & 
Zhivotovsky, 2014). The results from Chu et al. (2018) and Jia et al. (2016) showed that 
miRNA and serum-based biomarkers can be a promising marker for the early detection of 
lung cancer (Chu et al., 2018; Jia et al., 2016). But as of now, Chu et al. (2018) found no 
high-quality clinical evidence supporting the implication of these biomarkers. 
While innovation of technology increases in our society, many researchers are 
using technologies to help them understand the process of biological materials and how it 
relates to cancer development. Eggert, Palavanzadeh, and Blanton (2017) examined early 
detection of lung cancer using cell-free DNA, miRNA, circulating tumor cells (CTCs), 
LDCT, and spiral CT. The study identified expired malignant or circulating cells, and 
metabolites associated with specific lung cancer types. As cited in Gingras (2018), Eggert 
et al. (2017) stated that the diagnosis of solitary pulmonary nodules can be elucidated by 
the miRNA sputum via real time-polymerase chain reaction before screening with LDCT, 
which could detect lung cancer 1‒4 years earlier than using LDCT and chest x-ray 
methods (Eggert et al., 2017). However, despite ongoing research and laboratory work, 
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there is still a lack of information and methodology regarding the gene pathways and 
metabolites produced, including byproducts of cancer metabolism (Eggert et al., 2017). 
Effective screening options are needed to provide a non-invasive approach to early 
detection of lung cancer using biomarkers, including circulating epithelial (CEpC), 
circulating tumor cell (CTCs), metabolomics, methylation markers, serum cytokine level, 
and neutrophil microRNA (miRNA). 
Since a high rate of false-positive CT scans are found in lung cancer detection, 
Gyoba, Shan, Wilson, and Bédard (2016) examined miRNA biomarkers in blood, plasma, 
serum, and sputum for early detection of lung cancer. It was discovered that biological 
fluids such as whole blood, plasma, serum, and sputum can contain miRNA levels that 
can serve as biomarkers for detection and diagnosis of lung cancer. According to Gyoba 
et al. (2016), the promise of miRNA being a biomarker for the early detection of lung 
cancer is high because (1) it is easier and more effective to detect circulating miRNAs 
and other biological fluids in small quantities compared with healthy patients, and (2) 
miRNA levels are altered in lung cancer patients (Gyoba et al., 2016). The dysregulation 
of miRNA may have different pathological and physiological conditions, such as cancer 
patients having higher miRNA and abnormal expression (increased or decreased) in 
miRNA levels (Gyoba eta l. 2016). Sensitivity as a percentage is used to calculate the 
probability that the biomarkers are positives in cancer cases. False-positive values are 
calculated as specificity in percentage, which is the probability that the biomarkers are 
desired (Gyoba et al., 2016). After comparing sensitivity and specificity values of 
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different miRNAs in sputum, Gyoba et al. (2016) defined 80% or higher as a good 
screening and diagnostic test using biomarkers (Gingras, M. 2018). 
Volume Doubling Times 
Stages of lung cancer can also be based on the volume doubling time (VDT) of a 
nodule, which is a key parameter in lung cancer screening that can be defined as the 
number of days in which the nodule doubles in volume (Kanashiki et at., 2012; Honda et 
al., 2009; Usuda et al., 1994). Kanashiki et at., (2012), Honda et al. (2009) and Usuda et 
al. (1994) studied VDT of lung cancer based on annual chest radiograph screening and 
compared it with computed tomography (CT) screening for patients with lung cancer. 
Kanashiki et at., (2012) stated that VDT helps to differentiate between benign and 
malignant pulmonary nodules (Kanashiki et at., 2012). Shorter VDT may reflect greater 
histological tumor aggressiveness that may have poor prognosis (Kanashiki et at., 2012). 
Honda et al. (2009) investigated the difference in doubling time between squamous cell 
carcinoma (SCC) and adenocarcinoma of solid pulmonary cancer. Honda et al. (2009) 
found the median doubling time of SCC lung cancers to be less than that of 
adenocarcinoma. Usudu et al. (1994) used univariate analyses for survival rates and 
multivariate analyses for significant factors affecting survival using the Cox proportional 
hazard model.  
Univariate analyses showed a significant difference in survival in relation to DT, 
age, gender, method of tumor detection, smoking history, symptoms, therapy, cell type, 
primary tumor (T) factor, regional node (N) factor, distant metastasis (M) factor, and 
stage. Usuda et al. (1994) found that DT was an independent and a significant prognostic 
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factor for lung cancer patients. The minimum size of lung cancer that can be detected on 
a chest X-ray has been reported to be 6 mm, the minimum DT was 30 days, and the 
maximum DT was 1,077 days (Usudu et al. (1994). The mean DT in patients with 
adenocarcinoma was significantly longer than in patients with squamous cell carcinoma 
and undifferentiated carcinoma (Usudu et al. (1994). The mean DT in patients with a T1 
lung cancer was significantly longer in patients with T2, T3, or T4 lung cancer. The 
survival rate in men was significantly lower than that of women, and a better survival rate 
was associated with long DT, not smoking, N0, resection, and absence of symptoms 
(Usuda et al., 1994). 
Knowledge Limitation 
Although 80%–85% of patients with lung cancer have a history of smoking, 
surprisingly only 10%–15% of smokers actually develop lung cancer. The screening 
method reduces lung cancer mortality with a high rate of false positives. Therefore, the 
higher likelihood of over-diagnosis has raised the question of how to best implement lung 
cancer screening (Kathuria et al., 2014; Gyoba et al., 2016). Early detection with age-
related factors that contribute to lung cancer may improve the diagnosis of lung cancer in 
early stages. Kathuria et al. (2014) found opportunities and challenges related to lung 
cancer screening using biomarkers and found that it could be a promising method. 
Developing highly sensitive and specific age-related biomarkers may improve mortality 
rates.  
Although there is a strong relationship between lung cancer and tobacco smoke, 
tobacco use must be the first target for preventing risk factors for lung cancer (de Groot et 
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al., 2018). The most important step is early screening to detect and prevent lung cancer 
for high-risk populations. It is possible that biomarker screening in blood and urine could 
detect lung cancer, as tumors may cause a high rate of circulating miRNA (Robles & 
Harris, 2016). However, miRNA screening has not yet been used to detect the risk of 
lung cancer (Robles & Harris, 2016). New treatment options will be required if more lung 
cancer patients can be identified at a younger age and early stage of disease. Low-dose 
CT can identify a large number of nodules, however, fewer than 5% are finally diagnosed 
as lung cancer. By using biomarker screening of MSC–miRNA signatures, false positives 
can be reduced (Robles & Harris, 2016). Therefore, biomarker screening may improve 
the efficacy of lung cancer screening.  
Theoretical Foundation 
The theoretical framework of this study is the CCC, which is a framework of the 
National Cancer Institute (NCI, n. d.). To operationalize the use of the CCC theoretical 
construction in this study, three research questions examined detection as it related to the 
second tenet: prevention through screening of this study. Despite LDCT and X-ray 
detection of lung cancer, these imaging screening found lung cancer at a late stage or 
stage IV. While researchers are still improving the effectiveness of lung cancer screening 
using biological markers, early detection through age recommendation was examined for 
annual preventive screening through CCC. The original purpose of this CCC framework 
was to view plans, progress, and priorities that will help highlight knowledge gaps about 
causal variants and demographics factors of lung cancer. Using these three items 
(etiology, prevention, and detection), the risk factors for cancer at the molecular level 
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were also examined to prevent and detect cancers as early as possible (NCI, n. d.). The 
first focus of the CCC framework was the etiology of lung cancer, which included 
demographic risk factors (i.e. age, gender, race/ethnicity), health behavior risk factors 
(i.e. cigarette smoking), and the risk factor of gene-environment interactions (i.e. caused 
changes DNA methylation and mutations in cells) that reflected the state of health of the 
patient with NSCLC. Based on the etiology of lung cancer, this study investigated why 
older White American men were more vulnerable to lung cancer than other age groups. 
Also included were how mutations increase as age increase, how gender can be 
susceptible to lung cancer, and why African Americans have a higher risk of cancer than 
other racial or ethnic groups. 
 The second focus of the CCC framework was prevention through screening. The 
purpose of the Task Force is to improve the health of all Americans by making an 
evidence-based recommendation about preventive screenings as a part of health 
promotion (USPSTF, 2015). Although imaging screening using LDCT and chest X-ray 
has decreased the risk of lung cancer, the rates of mortality and morbidity of lung cancer 
remain stable and have not significantly decreased over the past decades (NCI, 2018; 
Patnaik et al., 2017). The U.S. Task Force recommends that LDCT screening should be 
discontinued once a person has not smoked for 15 years or develops a health problem that 
substantially limits life expectancy (USPSTF, 2015).  
The third focus of the CCC framework is detection. There is limited literature on 
how long it takes for cancer to develop after cell mutations. Cancer development starts at 
the cellular level and takes approximately 20‒40 years after cell mutations (Adams et al., 
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2015; Wagner et al., 2016). Effectiveness in screening is crucial to preventing lung 
cancer. Moreover, the evaluation of demographic risk factors (age, gender, 
race/ethnicity), environmental risk factors (cigarette smoking and other substances), 
gene-environmental interaction (changes in DNA and mutations in cells), and 
geographical risk factor may increase our knowledge of how differences in cancer cells 
grow based on these risk factors. The evaluation of demographic data, health behaviors, 
and gene-environmental interactions helped us understand how cancers begin and how to 
detect it at an early stage. 
This framework can be a foundation of how researchers should continue to 
develop appropriate strategies to prepare for the evaluation of biomarkers for early 
detection of lung cancer. The CCC framework may reduce the challenge of preventive 
screening studies by explaining the association of well-known risk factors of lung cancer 
at a molecular level. However, there is limited literature on how carcinogens in cigarette 
smoke increase the risk of mutation and how an increase in age increases the risk of 
mutations (Bakulski et al., 2019).  
The study of gene-environment interaction (changes in DNA and mutations) that 
can contribute to lung cancer is understudied. Since technology has changed our 
understanding of cancer development at a molecular level, the framework of CCC can be 
used with existing findings for the early detection of lung cancer. Based on the 
underlying framework of CCC, both internal and external risk factors’ role in lung cancer 
development were investigated: age, gender, race/ethnicity, and gene-environment 
interaction. The findings from this dissertation improved our understanding of the 
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epidemiology of external and internal risk factors that contribute to the development of 
lung cancer. In addition, the results provided information for future clinical study using a 
blood-based test for the early detection of lung cancer. 
Transition and Summary 
The main point of this study was to improve our understanding of how age-related 
risk factors that contribute to lung cancer help us understand the epidemiology of lung 
cancer. The investigation of TNM stages and the age of diagnosis presumed that the 
observed variation reflected the influence of cigarette smoke, age, gender, race/ethnicity, 
and environment as a genetic factor in lung cancer patterns. The finding helped not only 
minimizing the burden of lung cancer but bridged a gap in our understanding of the 
implication of epigenetics. Despite an improvement in imaging screening, the images that 
are produced by chest X-rays and LDCT screening have some drawbacks for effective 
screening (USPTF, 2018). Because of the lack of effective screening, lung cancer is still 
extremely lethal in the United States. To make age-related factors that contribute to 
cancer recognizable in the public health field, this dissertation has increased the 
knowledge of how the histology of lung cancer and TNM stages differ in age groups of 
population using SEER data. Chapter 2 (recent literature reviews) details how biomarkers 
of aging can be related to cancer, as an accumulation of carcinogens increases with aging. 
It is hoped that this research will bridge a gap in the lack of understanding of how age-




Chapter 3: Methodology 
Introduction 
RQ1: Is there a significant association between age at diagnosis and the stages of 
presentation of lung cancer after controlling for demographic factors: gender, 
race/ethnicity, and geographic region? 
Ho1: There is no significant association between age at diagnosis and the stage of 
presentation of lung cancer after controlling for demographic factors: gender, 
race/ethnicity, and geographic region. 
Ha1: There is a significant association between age at diagnosis and the stage of 
presentation of lung cancer after controlling for demographic factors: gender, 
race/ethnicity, and geographic region.   
A chi-squared test of independence was performed to examine the association 
between the stages of lung cancer and age groups after controlling for 
demographic risk. 
RQ2: Is there a significant association between the stage of lung cancer and 
demographic factors gender, race/ethnicity, and geographic regions after controlling for 
age?  
Ho2: There is no significant association between the stage of lung cancer and 
demographic factors. 
Ha2: There is a significant association between the stage of lung cancer and 
demographic factors.  
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The chi-squared test was used to examine the association between stages of lung 
cancer and demographic risk factors after controlling for age. 
 
RQ3: Is there any significant relationship between the stage of lung cancer, age 
and demographic factors?  
H03: There is no significant relationship between the stage of lung cancer, age, 
and demographic factors. 
Ha3: There is a significant relationship between the stage of lung cancer, age and 
demographic factors. 
Multinomial regression analysis was performed the find the association between 
stages of lung cancer, age, and demographic risk factors.  
Research Design and Rational 
This study used data from the National Cancer Institute Surveillance, 
Epidemiology, and End Results (SEER) program (November 2010 submission). The data 
was on lung cancer patients recorded during 2010‒2015 in the SEER database. The 
SEER program provides U.S. cancer statistics in an effort to reduce the cancer burdens in 
the U.S. population. NCI’s Division of Cancer Control and Population Sciences (DCCPS) 
support the SRP (NCI, n. d.). The data included diagnosis in cancer cases from 2010‒
2015 from state registries that were based on the 2010 U.S. Census data (NCI, n. d.). The 
two major types of cancer registries included population-based registries and hospital-
based registries, including special cancer registries. The population-based registries 
recorded all cases from a particular geographical area such as metropolitan and non-
metropolitan areas with an emphasis on the use of the data for epidemiology. Population-
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based registries were designed to determine cancer patterns among various populations, 
monitor cancer trends over time, guide planning, and evaluate cancer control efforts to 
help prioritize health resource allocations, and advance clinical, epidemiological, and 
health services research (NCI, n. d.).   
As lung cancer data were collected on the whole study population at a single point 
in time, a cross-sectional study was used to examine the relationship between lung 
cancer, age at diagnosis, and demographic factors. This cross-sectional study provided 
information about the frequency of lung cancer in a population during 2010‒2015. To 
observe the correlations between independent and dependent variables for this study, age 
at diagnosis, the stages of presentation of lung cancer, and demographic factors (gender, 
race/ethnicity, health behaviors, and geographical regions) were investigated. Although a 
cross-sectional study cannot demonstrate the cause-and-effect of independent and 
dependent variables, the result produced inferences about possible relationships to 
support further research.  
Comparison of the age groups of patients [(45‒49), (50‒54), (55‒59), (60‒64), 
(65‒69), (70‒74), (75‒79), and (80‒84)] who were diagnosed with lung cancer in 
different stages were analyzed. To increase the accuracy of the result, the variables 
gender, race/ethnicity, and geographical region were included in this study using X2 tests, 
odd ratio, and multinomial analysis. As bias in sample size can distort the result of the 
outcome, power analysis for the sample size was performed using G*Power (G*power 
3.1 manual, 2017) in order to reduce the effect of bias from the sample size. The 
G*power analysis showed that the estimated size would be 3,670. The purpose of a cross-
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sectional study was to determine whether there was any correlation between independent 
and dependent variables. However, this type of study can be limited in its ability to draw 
valid conclusions about any association or possible causality, because risk factors and 
outcomes are measured simultaneously. 
To find consistent results, this quantitative research method included chi-squared 
and multinomial analyses to elucidate the association between age at diagnosis, stages of 
presentation of lung cancer, and demographic risk factors. As younger ages at diagnosis 
for lung cancer have been reported for several cancer types (Robbins et al. 2014), the 
result of this study may help provide a recommendation for annual screening for lung 
cancer with the most effective method in adults aged 45 years and older who are both 
smokers and non-smokers. Reducing the age limitation for preventive screening may 
overcome the lack of effectiveness in lung cancer screening for early detection of lung 
cancer. Increasing knowledge of how age-related factors contribute to lung cancer may 
reduce the rate of morbidity and mortality caused by lung cancer. The hypothesis of this 
study was to investigate how age at diagnosis may predict outcomes in a patient who is in 
the early stages of lung cancer, as age and mutations are the most important predictors of 
prognosis in lung cancer patients (Wang et al., 2019; White et al., 2015). Although there 
may not be any cause-and-effect between age at diagnosis and the stages of presentation 
of lung cancer, older patients still may have a bad a prognosis with the worst outcome. 
Thus, hypotheses based on age-related factors that contribute to lung cancer may 




This study was conducted using publicly available data obtained by signing a 
Surveillance, Epidemiology, and End Results (SEER) Research Data Agreement for 
secondary data analysis. Data on lung cancer specific mortality and patients who were 
diagnosed between 2010‒2015 were extracted from SEER‒18 Registries (2010‒2017 
dataset). The SEER program collected cancer data by identifying people with cancer who 
were diagnosed with cancer or received cancer care in hospitals, outpatient clinics, 
radiology department, doctors’ offices, laboratories, surgical cancers, or from other 
providers (such as pharmacists) who diagnose or treat cancer patients (NCI, n. d. a). After 
removing identifying information, data were placed into five categories: stage of lung 
cancer, age at diagnosis, gender, race/ethnicity, and geographical region. Data were 
collected on the whole study population at a single point in time to examine the 
relationship between age at diagnosis and the stages of presentation of lung cancer (NCI, 
n. d.). Cross-sectional studies showed the association between and exposure and an 
outcome in a population at a given point in time. Thus, it was useful to inform and plan 
for health screenings.  
The study population comprised lung cancer patients with the International 
Classification of Disease for Oncology, 7th Edition. SEER collects cancer incidence data 
from population-based cancer registries covering approximately 34.6 percent of the U.S. 
population. This study collected data on patient demographics, age at diagnosis, stage at 
diagnosis, geographical regions, and deaths attributable to lung cancer. The geographical 
regions of SEER‒18 registries include (1) Alaska Native Tumor Registry, (2) 
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Connecticut Registry, (3) Detroit Registry, (4) Atlanta Registry, (5) Greater Georgia 
Registry, (6)  Rural Georgia Registry, (7) San Francisco-Oakland Registry, (8) San Jose-
Monterey Registry, (9), Greater California Registry, (10) Hawaii Registry, (11) Iowa 
Registry, (12) Kentucky Registry, (13) Los Angeles Registry, (14) Louisiana Registry, 
(15) New Mexico Registry, (16) New Jersey Registry, (17) Seattle-Puget Sound Registry, 
and (18) Utah Registry. Patient demographics information identified the current patient, 
age, gender, race/ethnicity, and geographical regions. Characteristics of lung cancer 
include (1) stage of cancer, (2) size of the tumor, (3) any spread of cancer into nearby 
tissue, (3) any spread of cancer to nearby lymph nodes, and (4) any spread of cancer to 
other parts of the body. To find the association between the age and presentation of lung 
cancer, age at diagnosis, mortality cases caused by lung cancer, and the metastatic 
patterns diagnosed with lung cancer were used. 
Methodology 
A cross-sectional study was appropriate for inferential analyses and for generating 
hypotheses. Using descriptive statistics, the study assessed the frequency and distribution 
of lung cancer among these age groups: [(45‒49), (50‒54), (55‒59), (60‒64), (65‒74), 
(75-79), and (80‒84)] based on the stages of lung cancer (stage: I, II, III, IV). A total of 
63,107 patients who were diagnosed with lung cancer during (2010‒2015) or had lung 
cancer as a cause-specific mortality met the eligibility criteria. All the lung cancer 
statistical analyses were performed using the Statistical Package for Social Science 
(SPSS, Inc., Chicago, IL, USA) software (version 25.0) for Windows. The inferential 
data were expressed as chi-squared, OR, and confidence intervals to describe the sample 
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under study. The incidence of lung cancer and age-related factors are important to assess 
the burden of disease in a specified population and in planning and allocating health 
resources. The available data on the incidence of lung cancer was obtained for the period 
2000‒2015 from the National Cancer Institute’s SEER Registries database using 
SEER*Stat (version 8.3.6).  
The demographic variables included age at diagnosis [(45‒49), (50‒54), (55‒59), 
(60‒64), (65‒74), (75‒79, and (80‒84)], gender (women and men), race/ethnicity 
(African American and White American), and geographical regions [(metropolitan 
counties: counties in metropolitan areas with a population greater than 1 million, counties 
in metropolitan areas with a population between 250,000 and 1 million, counties in 
metropolitan areas with a population of less than 250,000) and non-metropolitan 
counties: counties that adjacent to a metropolitan area and not adjacent to a metropolitan 
area)] and the presentation of lung cancer stage (I, II, III, IV). To reduce potential bias in 
a cross-sectional study, non-responses and data on un-staged lung cancer were excluded 
from the study. The exclusion criteria were (1) patients without a pathological diagnosis, 
(2) cases from 2016 and 2017 because TNM stages were not identified (3) patients 
without any TNM information, and (4) patients with non-cancer specific death (missing 
data or unknown or un-staged). The primary endpoint of the study was calculated from 
the date of diagnosis to the data of cancer-specific death or the last follow-up. The study 
was approved by Walden IRB.  
A request was made to have access to SEER data (using the link 
https://seer.cancer.gov/seertrack/data/request/) after receiving Walden IRB approval. The 
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SEER program processed the data usage request after receiving a signed agreement and 
providing a personalized SEER Research Data Agreement. SEER data involves no more 
than a minimal risk to the participants and meets other standards: data do not include 
vulnerable populations such as prisoners, children, veterans, or cognitively impaired 
persons. However, the data include terminally ill patients of lung cancer without their 
identity.   
Data Analysis Plan 
RQ1: Is there a significant association between age at diagnosis and the stages of 
presentation of lung cancer after controlling for demographic factors: gender, 
race/ethnicity, and geographic region? 
Ho1: There is no significant association between age at diagnosis and the stage of 
presentation of lung cancer after controlling for demographic factors: gender, 
race/ethnicity, and geographic region. 
Ha1: There is a significant association between age at diagnosis and the stage of 
presentation of lung cancer after controlling for demographic factors: gender, 
race/ethnicity, and geographic region.   
The chi-squared test was used to examine the association between age at 
diagnosis and stages of presentation of lung cancer after controlling for 
demographic risk factors. 
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RQ2: Is there a significant association between the stage of lung cancer and 
demographic factors (gender, race/ethnicity, and geographic regions) after controlling for 
age at diagnosis?  
Ho2: There is no significant association between the stage of lung cancer and 
demographic factors after controlling for age at diagnosis. 
Ha2: There is a significant association between the stage of lung cancer and 
demographic factors after controlling for age at diagnosis.  
The chi-squared test was used to examine the association between the stages of 
presentation of lung cancer and demographic risk factors after controlling for age. 
RQ3: Is there any significant relationship between the stage of lung cancer, age at 
diagnosis, and demographic factors?  
Ho3: There is no significant relationship between the stage of lung cancer, age at 
diagnosis, and demographic factors. 
Ha3: There is a significant relationship between the stage of lung cancer, age at 
diagnosis, and demographic factors. 
The multinomial logistic regression test was used to examine the association 
between the stages of presentation of lung cancer, age at diagnosis, and 
demographic risk factors. 
Ethical Consideration 
The ethical issue faced with this study was compliance with the Health Insurance 
Portability and Accountability Act (HIPPA) regulations. SEER data is abstracted from 
medical records at healthcare facilities, including hospitals, physicians’ offices, and 
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pathology laboratories, and follows the North American Association of Central Cancer 
Registries (NSSCCR) data standards. SEER data contain information about geographic 
location at the county level as well as dates of receiving health care services and data on 
diagnosis. Because of these variables, the data from the SEER program are considered a 
limited data set by HIPAA requirements. To protect human subjects and the stakeholders, 
an Internal Review Board (IRB) approval from the Walden IRB was obtained. The 
Walden IRB’s ethics review focuses on the protection of the data stakeholders: anyone 
who contributed significantly to the creation of the SEER data as well as human 
participants in the data. This dissertation includes ethical considerations of the IRB 
approval criteria required for all students to address analysis of data on living persons. 
Based on these criteria from section (46.111(b) of 45 CFR 46), this dissertation is exempt 
from the full IRB review for the use of anonymized data. 
Threats to Validity 
A trial study was performed to evaluate whether using the SEER data would be 
feasible and to inform the best way to conduct the future full-scale project. All the 
available lung cancer cases are stratified by age groups of the patients. The four main 
components in this study included (1) process―whether the eligibility criteria would be 
feasible; (2) resources―how much time the main study would take to complete; (3) 
management―whether there would be a problem with available data; and (4) all the data 
needed for the main study to test before data analysis. The trial study helped clarify the 
barriers to and challenges of identifying the strengths and limitations of a planned larger-
scale study and testing the design, methodology, and feasibility of the main study. The 
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threats to external validity are any factors within a study that reduce the generalizability 
of the results (Laerd Dissertation, n. d.). The external validity is the extent to which 
findings can be generalized to the whole population, and it can distort the result of the 
main study. The main threats to external validity in this dissertation included (1) biases 
with all available lung cancer cases, (2) constructs, methods, and confounding, and (3) 
the real world versus the experimental world. Since the goal is for this quantitative study 
to be generalized to the whole population, using all the available lung cancer cases across 
populations can be the most significant threat to external validity.  
On the other hand, internal validity is the extent to which only age at diagnosis 
(independent variable) caused the changes in the stage of presentation of lung cancer 
(dependent variable). This was a potential threat to internal validity. The threats to 
internal validity included the effects of history, maturation, main testing, mortality, 
statistical regression, and instrumentation. To eliminate the threats to internal validity, 
only lung cancer patients who were diagnosed with lung cancer during the years 2010‒
2015 were included. The data included demographic information such as age at 
diagnosis, gender, race/ethnicity, geographic regions, and stages of presentation of lung 
cancer during 2010‒2015. The standardized instrument included the measurement of 
stages of presentation of lung cancer in a subgroup of stages: I, II, III, and IV. All the 
available lung cancer cases in SEER program were used. All patients diagnosed with lung 




This research used a cross-sectional study design, which is a type of observational 
study that analyzes data from a population at a specific time. For the best outcome of this 
study, only lung cancer was included. The results explained the association between age 
at diagnosis and the stages of presentation of lung cancer based on the representative 
population at a specific point in time. This study investigated participants who were 
usually separated by age in groups, gender, race/ethnicity, and the stages of presentation 
of lung cancer. Therefore, a cross-sectional study design was useful to determine the 
burden of disease or the health needs of a population. To increase the accuracy of the 
result, four tests were performed: normal distribution, chi-squared test, and multinomial 
analyses on categorical variables. Before data analyses were conducted, the study tested 
for normal distribution of the data. Then, chi-squared test and multinomial analyses were 
continued. The chi-squared analysis described one characteristic―age at diagnosis―for 
each stage of lung cancer.   
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Chapter 4: Results  
Introduction 
RQ1: Is there a significant association between age at diagnosis and the stages of 
presentation of lung cancer after controlling for demographic factors? 
Ho1: There is no significant association between age at diagnosis and the stage of 
presentation of lung cancer after controlling for demographic factors. 
Ha1: There is a significant association between age at diagnosis and the stage of 
presentation of lung cancer after controlling for demographic factors.   
The chi-squared test was used to examine the association between age at 
diagnosis and stages of presentation of lung cancer after controlling for 
demographic risk factors. The results of the association between stage I compared 
with other stages (II, III, and IV), stage II compared with other stages (II, III, and 
IV), and IV compared with other stages (II, III, and IV) and age groups at 
diagnosed were statistically significant - stage I [X2 (7, N=63,107) = 695.94], 
stage II [X2 (7, N=63,107) = 193.35], and stage IV [X2 (7, N=63,107) = 609.80], at 
P < 0.05 respectively (Table 3). Therefore, the null hypothesis was rejected. 
RQ2: Is there a significant association between the stage of lung cancer and 
demographic factors gender, race/ethnicity, and geographic regions after controlling for 
age at diagnosis?  
Ho2: There is no significant association between the stage of lung cancer and 
demographic factors after controlling for age at diagnosis. 
74 
 
Ha2: There is a significant association between the stage of lung cancer and 
demographic factors after controlling for age at diagnosis.  
The chi-squared test was used to examine the association between stages of lung 
cancer and demographic risk factors after controlling for age at diagnosis. The 
chi-squared test analysis displayed a statistically significant relationship between 
stages of lung cancer and gender X2 (3, N=63,107) =38.93; race, X2 (3, N=63,107) 
= 113.44; and geographical regions X2 (3, N=63,107)=20.94, P < .01 after 
controlling for age at diagnosis (Table 4). Therefore, the null hypothesis was 
rejected.  
RQ3: Is there any significant relationship between the stage of lung cancer, age at 
diagnosis, and demographic factors?  
Ho3: There is no significant relationship between the stage of lung cancer, age at 
diagnosis, and demographic factors. 
Ha3: There is a significant relationship between the stage of lung cancer, age at 
diagnosis, and demographic factors. 
The multinomial logistic regression analysis was used to examine the association 
between stages of lung cancer, age at diagnosis, and demographic risk factors. 
The purpose of these research questions was to identify any possible associations 
between the age of an individual and the stages of presentation of lung cancer. Lung 
cancer patient records were obtained from the special SEER database from 2000 to 2017. 
The inclusion criteria were definitive NSCLC and SCLC diagnosis by pathology. The 
exclusion criteria used for my data collection were as follows: (1) patients who were 
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younger than age 45 years because there were a small number of people diagnosed with 
lung cancer were younger than 45 years old, (2) patient without any TNM information, 
and (3) mortality cases that were not caused by lung cancer. SEER*Stat Version 8.3.6.1 
(2019; National Cancer Institute Statistics Branch, Bethesda, MD; 
www.seer.Cancer.gov/seerstat) was used to identify all patients with lung and bronchus 
cancer during (2010‒2015) based on the International Joint Committee on Cancer 
(AJCC) 7th edition. The demographics of patients included gender, age at diagnosis, 
race/ethnicity, and geographic region.  
The incidence of lung cancer was extracted from the CS-Derived American Joint 
Committee on Cancer (AJCC), 7th edition (2010‒2015) with the stages cancer, stages of 
tumor (T), stages of node (N), and metastasis (M). The proportion of lung cancer was 
classified by 5-year intervals [(45‒49), (50‒54), (55‒59), (60‒69), (70‒74), (75‒79), (80‒
84)]. The primary endpoint of the study was mortality cases that are attributable to lung 
cancer, and the cancer cases were confirmed using direct visualization without 
microscopic confirmation, positive histology, radiography without microscopic 
confirmation, positive microscopic confirmation, method not specified, and cause-
specific death. The secondary endpoint for this study was analyzed by the chi-squared 
test and Post Hoc test. Quantitative analyses were conducted using the chi-squared test on 
categorical variables and multinomial logistic regression test. Differences in patients’ 
demographics, cancer characterizations, and cancer outcomes among subgroups are 
summarized in Table 3. The study was approved by institutional ethics committee of 




All statically analyses were performed using the SEER*Stat and the IBM 
Statistical Package for Social Science (SPSS) Statistics (SPSS, Inc, Chicago, IL, USA) 
software, version 25. The frequency analysis was used to describe the sample under 
study, and statistics data were expressed as chi-squared tests to find the relationship 
between the age at diagnosis and the stages of lung cancer. After testing the normal 
distribution of the data set, baseline characteristics (demographic and clinical staging data 
of each patient) were analyzed using the (X2) test. The association between age at 
diagnosis and gender, race/ethnicity, stages of lung cancer, and geographic region were 
individually evaluated by (X2) test (Tables 5).  All risk factors were tested with X2, OR, 
95% CI test, and P < 0.05. The four main components in this study included (1) 
process―whether the eligibility of criteria were feasible; (2) resources―how much time 
the main study would take to complete; (3) management―whether there would be a 
problem with available data; and (4) all the data needed for the main study. The external 
threat included extremely large number lung cancer cases during the years 2010‒2015. 
The stages of presentation of lung cancer were normally distributed, and a P-value of ≤ 
0.05 was considered statistically significant. To reduce the sample size, lung cancer cases 
from 2010‒2015 were used for the main study. All statistical analyses and the bar graphs 




Descriptive Statistic Results 
In this quantitative, cross-sectional study, a total of 63,107 cases (N=63,107) of 
lung cancer from 2010‒2015 met the eligibility criteria. The distribution of age groups, 
stages of presentation of lung cancer, gender, race/ethnicity, and geographical regions are 
summarized in Table 2.  
Inferential Analyses Results 
The inferential analyses used chi-squared, odd ratio, and multinomial analysis. 
Research question 1 investigated the association between stages and age groups at 
diagnosis after controlling for demographic factors. The chi-squared test of research 
question 1 showed a statistically significant association between the stages of 
presentation of lung cancer and the age at diagnosis: stage I, [X2 (7, N=63,107) = 696.94], 
stage II [X2 (7, N=63,107) = 191.35], and stage IV [X2 (7, 63,107) = 608.80], at P < 0.05 
respectively (Table 3). The chi-squared test of research question 2 showed a  statistically 
significant relationship between stages of lung cancer and demographic risk factors after 
controlling for age at diagnosis―gender:  X2 (3, N=63,107) =38.93; race: X2 (9, 
N=63,107) = 113.44, and geographical regions: X2 (3, N=63,107)=20.94, P < .01 
respectively (Table 4). The results of multinomial analyses displayed the risk of people 
diagnosed with stage I lung cancer in age group (45‒49) years old was 75.4% lower than 
stage IV, stage II lung cancer in age group (45‒49) years old was 66.8% lower than stage 
IV, and stage III lung cancer in age group (45‒49) was 26.4% lower than stage IV, P < 




Descriptive Statistics of Sex, Race, Age Groups, and Stages of Presentation of Lung 
Cancer 
 
 Frequency Percent 
Sex   
Women 28,035 44.4 
Men 35,075 55.6 
Total 63,107 100.0 
   
Race/Ethnicity   
White 55,049 87.2 
Black 8,058 12.8 
Total 63,107 100.0 
   
Age   
45‒49 1,536 2.4 
50‒54 3,831 6.1 
55‒59 6,550 10.4 
60‒64 8,967 14.2 
65‒70 11,548 18.3 
70‒74 11,942 18.9 
75‒79 10,734 17.0 
80‒84 7,999 12.7 
Total 63,107 100.0 
   
Geographical Regions   
Metropolitan counties 5,2835 83.7 
Nonmetropolitan counties 10,272 16.3 
Total 63,107 100.0 
   
Stage   
Stage I 8,319 13.2 
Stage II 5,943 9.4 
Stage III 15,441 24.5 
Stage IV 33,404 52.9 
Total 63,107 100.0 




RQ1: Is there a significant association between age at diagnosis and the stages of 
presentation of lung cancer after controlling for demographic factors gender, 
race/ethnicity, and geographic region? 
Ho1: There is no significant association between age at diagnosis and the stage of 
presentation of lung cancer after controlling for demographic factors gender, 
race/ethnicity, and geographic region. 
Ha1: There is a significant association between age at diagnosis and the stage of 
presentation of lung cancer after controlling for demographic factors: gender, 
race/ethnicity, and geographic region.   
A chi-squared test of independence was performed to examine the relationship 
between stags of lung cancer [stage I (13.2%), stage II (9.4%), stage III (24.5%), and 
stage IV(52.9%) and age groups [(45‒49), (50‒54), (55‒59), (60‒64), (65‒69), (70‒74), 
(75‒79), and (80‒84)] at diagnosis. The results were statically significant for stage I (X2 
(7, N=63,107) = 695.94), stage II (X2 (7, N=63,107) = 191.35), and stage IV (X2 (7, 
N=63,107) = 609.80), at P < 0.01 respectively. However, the result for stage III (X2 (7, 
N=63,107) = 695.94) was not statistically significant (Table 2). Therefore, the null 
hypothesis was rejected for stage I, II, and IV, and the alternative hypothesis was 
accepted. However, compared with other stages (stage I, II, and IV), the result of stage III 
and age groups was not statistically significant at X2 (7, N=63,107) = 11.84 P > .05 (Table 






Chi-squared Tests Results of the Association Between Age at Diagnosis and Stages of 
Presentation of Lung Cancer 
 Age Groups     
Stage 45‒49 50‒54 55‒59 60‒64 65‒69 70‒74 75‒79 80‒84 Total X2 DF P-value 
Stage I 88 275 512 926 1,560 1,771 1,790 1,397 8,319    
Other 1,448 3,556 6,035 8,041 9,988 10,171 8,944 6,602 54,788 695.94 7 0.00* 
Total 1,536 3,831 6,550 8,967 11,548 11,942 10,734 7,999 63,107    
Stage II 94 251 475 734 1,075 1,201 1,192 921 5,943    
Other 1,442 3,580 6,075 8,233 10,473 10,741 9,542 7,078 57,164 191.35 7 0.00* 
Total 1,536 3,831 6,550 8,967 11,548 11,942 10,734 7,999 63,107    
Stage III 357 977 1,650 2,182 2,822 2,941 2,649 1,863 15,441    
Other 1,179 2,854 4,900 6,785 8,726 9,001 8,085 6,136 47,666 11.84 7 0.11 
Total 1,536 3,831 6,550 8,967 11,548 11,942 10,734 7,999 63,107    
Stage IV 997 2,328 3,913 5,125 6,091 6,029 5,103 3,818 33,404    
Other 539 1,503 2,637 3,842 5,457 5,913 5,631 4,181 2,9703 609.80 7 0.00* 
Total 1,536 3,831 6,550 8,967 11,548 11,942 10,734 7,999 63,107    





Figure 1. The Association Between Stages of Lung Cancer and Age groups. 
 
Research Question #2: Is there a significant association between the stage of lung cancer 
and demographic factors after controlling for age?  
Ho2: There is no significant association between the stage of lung cancer and 
demographic factors after controlling for age. 
Ha2: There is a significant association between the stage of lung cancer and 
demographic factors after controlling for age.  
A chi-squared test of independence was performed to examine the association 
between the stage of lung cancer and respective demographic factors using SPSS. The 
results were statically significant for sex: X2 (3, N=63,107) = 38.93; race: X2 (3, 
N=63,107) = 113.44; and geographical regions:  X2 (3, N=63,107) = 20.94, at P < 0.01 
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respectively (Table 4, Figures 2, 3, & 4) after controlling for age. Therefore, the null 
hypothesis was rejected, and the alternative hypothesis was accepted.  
Table 4 
Chi-squared Test Results of Stages of Presentation of Lung Cancer and Demographic Risk 
Factors 
 
 Stage I Stage II Stage III Stage IV Total X2 DF P-value 
Sex         
Women 3,957 2,587 6,773 14,718 28,035 38.93  3     .00* 
Men 4,362 3,356 8,668 18,686 35,072    
Total 8,319 5,943 15,441 33,404 63,107    
         
Race         
White 7,509 5,277 13,468 28,795 55,049    
Black 810 666 1,973 4,609 8,058 113.44 3 .00* 
Total 8,319 5,943 15,441 33,404 63,107    








1,397 1,068 2,541 5,266 10,272 20.94 3 .00* 
Total 8,319 5,943 15,441 33,404 63,107    





Figure 2. The Association Between Gender and Stages of Lung Cancer 
 





Figure 4. The Association Between Geographic Regions and Stages of Lung Cancer 
 
Research Question #3: Is there any significant relationship between the stage of lung 
cancer, age at diagnosis, and demographic factors?  
 Ho3:  There is no significant relationship between the stage of lung cancer, age at 
diagnosis, and demographic factors.  
 Ha3:  There is a significant relationship between the stage of lung cancer, age at 
diagnosis, and demographic factors.  
The multinomial logistic regression analysis was performed to the find the 
association between stages of lung cancer, age at diagnosis, and demographic risk factors. 
The risk of women diagnosed with stage I lung cancer was 14.1% [OR:1.141, 95% CI: 
1.087–1.198] higher than men diagnosed with stage IV lung cancer in non-metropolitan 
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counties, P < 0.05 (Table 5). However, the risk for women diagnosed with stage II and 
stage III lung cancer compared with the risk for men diagnosed with stage IV lung cancer 
in metropolitan areas was not statistically significant at [OR:.975, 95% CI: .922–1.032] 
and stage III lung cancer is [OR:.991, 95% CI:.954 – 1.030], P > 0.05, respectively 
(Table 5). The risk for African Americans diagnosed with stage I lung cancer was 23.9% 
[OR:.761, 95% CI:.702–.824], stage II lung cancer was 13.5% [OR:.865, 95% CI:.798–
.944], and stage III lung cancer was 6.1% [OR:.939, 95% CI:.887–.995] lower than the 
risk for White Americans diagnosed with stage IV lung cancer in non-metropolitan areas 
at P < .05. The risk for people diagnosed with stage I, II, and III lung cancer in 
metropolitan counties (metropolitan areas > 1 million population, counties in 
metropolitan areas of 250,000 to 1 million population, and metropolitan areas of less than 
250,000 population) was 9.8%, 15.9%, and 5.2% lower than people diagnosed with stage 














Multinomial Regression Analysis of the Association between Stages of Lung Cancer and 
Demographic Risk Factors 
     95% CI  
Variable  B Std. 
Error 
Wald Exp(B) LL UL P-
value 
Stage I         
Age 
Groups 
45‒49 -1.404 .116 147.400 .246 .196 .308 .00* 
50‒54 -1.103 .071 239.710 .332 .289 .382 .00* 
55‒59 -1.003 .057 313.883 .367 .328 .410 .00* 
60‒64 -.687 .048 208.310 .503 .458 .552 .00* 
65‒69 -.346 .042 66.968 .707 .651 .768 .00* 
70‒74 -.213 .041 26.571 .808 .745 .876 .00* 
75‒79 -.037 .042 .803 .963 .888 1.045 .37 
Sex Women .132 .025 28.23 1.141 1.087 1.198 .00* 
Race Black -.273 .041 44.96 .761 .702 .824 .00* 
Metropolitan Counties -.103 .033 9.463 .902 .845 .963 .02* 
Stage II         
Age 
Groups  
45‒49 -.935 .114 67.109 .393 .314 .491 .00* 
50‒54 -.797 .076 109.593 .451 .388 .523 .00* 
55‒59 -.683 .061 124.978 .505 .448 .569 .00* 
60‒64 -.521 .054 92.809 .594 .534 .660 .00* 
65‒69 -.316 .050 40.622 .729 .662 .804 .00* 
70‒74 -.194 .048 16.040 .823 .749 .906 .00* 
75‒79 -.034 .049 .485 .967 .878 1.064 .49 
Sex Women -.025 .029 .758 .975 .922 1.032 .39 
Race Black -.145 .045 10.622 .865 .793 .944 .00* 
Metropolitan Counties -.173 .037 21.57 .841 .782 .905 .00* 
Stage III         
Age 
Groups  
45‒49 -.306 .068 20.277 .736 .645 .841 .00* 
50‒54 -.146 .048 9.355 .864 .787 .949 .00* 
55‒59 -.143 .041 12.199 .867 .800 .939 .00* 
60‒64 -.135 .038 12.414 .874 .811 .942 .00* 
65‒69 -.052 .035 2.029 .950 .884 1.02 .15 
70‒74 .000 .036 .000 1.00 .931 1.073 .99 
75‒79 .062 .037 2.788 1.064 .989 1.144 .09 
Sex Women -.009 .020 .205 .991 .954 1.030 .65 
Race Black -.062 .029 4.601 .939 .887 .995 .03* 
Metropolitan Counties -.053 .027 3.996 .948 .900 .999 .05* 
        
87 
 
Note: Reference categories = Stage IV, Age (80-84), men, White, nonmetropolitan counties. CI=confidence 
interval, LL = lower limit, UL = upper limit. p-value set at 0.05, * indicates p-value < 0.05. 
 
The risk for people diagnosed with stage I lung cancer in age group (45–49) years 
was 75.4% [OR:.246, 95% CI=.196–.308], in age group (50–54) was 66.8% [OR:.332, 
95% CI=.289–.382], in age group (55–59) was 63.3% [OR:.367, 95% CI=.328–.410], in 
age group (60–64) was 49.7% [OR:.503, 95% CI=.458–.552], in age group (65–69) years 
old was 29.3% [OR:.707, 95% CI=.651–.768], and in age group (70–74) years old was 
19.2% [OR:.808, 95% CI=.745–876] lower than people diagnosed with stage IV lung 
cancer in age group (80–84) years old, and was statistically significant at P < 0.01 
respectively. However, the risk for people diagnosed with stage I lung cancer in age 
group (75‒79) was not statistically significant at [OR:963, 95% CI=.888-.1.045], P = 
0.37 (Table 5).  
The risk for people diagnosed with stage II lung cancer in age group (45–49) 
years old was 60.7 % [OR:.393, 95% CI= .314–.491], age group (50–54) years old was 
54.9 % [OR:.451, 95% CI= .388–.523], age group (55–59) years old is 49.5 % [OR:.505, 
95% CI= .448–.569], age group (60–64) years old is 40.6 % [OR:.594, 95% CI= .534–
.660], and age group (65–69) years old was 27.1% [OR:.729, 95% CI= .662–.804], and 
age group (70–74) years old was 17.7 % [OR:.823, 95% CI= .74–.906] lower than the 
risk of age group (80–84) years old diagnosed with stage IV lung cancer and was 
statistically significant, P < 0.01 respectively. However, the risk of people diagnosed with 
stage II lung cancer in age group (75‒79) years old was not statistically significant 
[OR:.486, 95% CI=.878‒1.064], P = 0.48 (Table 5).  
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The risk for people diagnosed with stage III lung cancer in age group (45–49) was 
26.4%, [OR:.736, 95% CI:.645–.841], age group of (50–54) was 13.6%, [OR:.864, 95% 
CI:.787–.949], age group (55–59) was 13.3 % [OR:.867 95% CI= .800–.939], age group 
(60–64) was 12.6% [OR:.874, 95% CI= .811–.942], lower than people with age group 
(80–84) years old diagnosed with stage IV lung cancer, P < .01 respectively. However, 
the risk for people diagnosed with stage III in age group (65–69), (70‒74), and (75‒79) 
was not statistically significant at [OR:.950, 95% CI=.884–1.020, P = 0.15]; [OR:.990, 
95% CI=.931‒1.073, P = 0.99]; [OR: 1.064, 95% CI=.989‒1.144, P = .09], P > 0.05 
(Table 5).  
The risk for women diagnosed with stage I lung cancer was 14.1%, [OR:.1.141, 
95% CI = .1.087‒1.198] higher than men with stage IV and the association between 
women and stage I lung cancer was statistically significant at P < 0.01. However, the risk 
for women diagnosed with stage II and III was not statistically significant [OR:.975, CI= 
.922‒1.032, P = 0.38] and [OR:.991, 95% CI=.954‒1.030, P = 0.65] (Table 5). The risk 
for African Americans diagnosed with stage I lung cancer was 23.9% [OR:.761, 95% CI= 
.702‒.824], stage II lung cancer was 13.5% [OR:.865, 95% CI= .793-.944, and stage III 
was 6.1% [OR:.948, 95% CI= .900‒.999] lower than White Americans diagnosed with 
stage IV lung cancer at P < 0.05 respectively (Table 5). The risk for people living in 
Metropolitan counties diagnosed with stage I lung cancer was 9.8% [OR:.902, 95% CI= 
.945-963], stage II lung cancer was 15.9% [OR:.841, 95% C=: .782‒.905], and stage III 
was 5.2% [OR:.948, 95% CI= .900‒.999] lower than stage IV lung cancer in non-
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Metropolitan counties and the association between Metropolitan counties and stages of 
lung cancer was statistically significant at P < 0.05 (Table 5).  
 
Summary 
The results of this study presented the association between the age groups and the 
stages of presentation of lung cancer. Under the age distribution associated with stages of 
lung cancer, the risk of stage IV cancer was significantly higher than stage I, II, and III 
(Figure 2). Multinomial regression analysis indicated the risk of people diagnosed with 
stage I lung cancer in age groups [(45–49), (50‒54), (55‒59), (60‒64), (65‒69), and (70‒
75)] years old was statistically significant at [OR: .246, 95% CI= .196‒.308], [OR: .332, 
95% CI: .289‒.382], (OR: 367, 95% CI= .328‒.410], [OR:503, 95% CI=.458‒.552], [OR: 
.707, 95% CI= .651‒.768], and [OR:.808, 95% CI= .745‒.876]; stage II lung cancer in 
age group [(45‒49), (50‒54), (55‒59), (60‒64), (65‒69), and (70‒74)], was statically 
significant at [OR: .393, 95% CI= .314‒.491], [OR: .451, 95% CI: .388‒.523], [OR: .505, 
95% CI=.448‒.569], [OR:.594 95% CI= .534‒.660], [OR: .729, 95% CI= .662‒.804], and 
[OR: .823, 95% CI= .749‒.906]; stage III lung cancer in age group (45‒49), (50‒54), 
(55‒59), and (60‒64), [OR: .736, 95% CI= .645‒.841], [OR: .864, 95% CI= .787‒.949], 
[OR: .867, 95% CI= .800‒.939], and [OR: .874, 95% CI= .811‒.942] at P < 0.05 
respectively (Table 5). However, there were no statistically significant association 
between stage I lung cancer and age group (75‒79) [OR:.370 95% CI:.888.1.045 at P = 
0.37; stage II lung cancer and age group (75‒79) [OR: .841, 95% CI= .781‒.905], and 
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stage III lung cancer in age group (65‒69), (70‒74), and (75‒79) were not statistically 
significant, P > 0.05 (Table 5).  
Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this dissertation was to provide an age recommendation for 
preventive screening to detect early stages of lung cancer. The results of this study 
indicated that each stage of lung cancer was a dependent risk predictor of lung cancer 
mortality. The nature of this research was a quantitative study using a cross-sectional 
design to examine data from age, stage, and demographic factors. Specifically, the 
differences in stages of lung cancer and age groups were analyzed. This quantitative 
method included stages of lung cancer analyses for age groups, and the chi-squared 
results indicated that stages I, III, and IV and age groups [(45‒49), (50‒54), (55‒59), 
(60‒64), (65‒69), (70‒74), and (75‒79)] were statistically significant: stage I, X2 (7, 
N=63,107) = 695.94, stage II, X2 (7, N=63,107) = 191.35, and stage IV, X2 (7, 63,107) = 
609.80, at P < 0.05 respectively. However, stage III and all age groups (45-84) were not 
statistically significant, P = 11 (Table 3). The results of multinomial analyses indicated 
low rates of stage I and stage II lung cancer in age group (45‒49) years old. Since lung 
cancer is asymptomatic and screening is not recommended for age groups (45‒49) and 
(50‒55), the actual rate of early stage lung cancer may not be accurately ascertained. 
Therefore, the results of our data analyses support updating the recommended age for 




Interpretation of the Findings 
This study delineated the distinct metastatic features of lung cancer in patients 
with different age groups, race groups, sex, and geographical regions (Adams et al., 
2015). As lung cancer is a malignant lung carcinogenesis characterized by cell mutations, 
the findings based on mortality rate were consistent with previous population-based 
studies on ages and different genders and races (Adams et al., 2015; Dorak & 
Karpuzoglu, 2012; Wang et al., 2015). Historically, social inequalities in the United 
States have caused African American populations to be more vulnerable to cancers and 
diseases (David et al., 2016; Toporowski et al., 2012). However, this study found that 
White Americans (87.2%) were more vulnerable to lung cancer than the African 
American population (12.8%). This could be due to inequality in health care, and more 
White Americans may have access to health insurance and were screened for early 
detection of lung cancer in this SEER‒18 registry population (Pickett & Wilkinson, 
2015). In this study, patients between ages (45‒84) and with stage (IV) lung cancer were 
more likely to be White than African American. The racial differences observed were 
likely to be a result of a complex relationship between screening access and etiological 
factors (age groups) across different racial and ethnic populations. Relevant information 
was included to explain the different stages of lung cancer across age groups and to 
support future research studies that focus on biomarkers of lung cancer based on age.  
Limitations of the Study 
This study had some limitations; for example, surgery and treatment might 
contribute to differences in stages of lung cancer mortality. Age groups 0‒44 and > 84 
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were excluded to decrease the sample sizes from both ends using lung cancer cases in 
SEER registries. Differences in lung-cancer specific mortality were identified in different 
age groups. Future cross-sectional studies focusing on biomarkers are needed to evaluate 
determinants of outcome.  
Recommendations 
As age and mutations increase the risk of lung cancer, earlier annual preventive 
screening is needed to detect earlier stages of lung cancer. Currently, the American 
Cancer Society recommends yearly lung cancer screening with LDCT for high-risk 
populations, those who are smokers, and those who have a genetic predisposition. For 
people at average risk for lung cancer, the American Cancer Society recommends starting 
regular screening at age 55. This age recommendation can be lowered to reduce the 
number of new cases of lung cancer and mortality, since cancer can take up to 20 years 
before it appears in the chest X-ray and LDCT. Since the purpose of cancer screening is 
to find cancer in people who are asymptomatic, early detection through screening based 
on age gives the best chance of finding cancer as early as possible.  
Summary 
The aim of this dissertation was to conduct a population study comprising 63,107 
subjects from SEER‒18 data to provide an age recommendation for annual preventive 
screening to implement social change. This dissertation provides information about how 
age-related factors can contribute to lung cancer and supports a policy recommendation 
for annual preventive screening to detect early stages of lung cancer for vulnerable 
populations: everyone over 45 years old, and both smokers and non-smokers. This 
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research will bridge a gap in the understanding of the association between age-related 
factors and lung cancer development. This project is unique because it addresses how a 
simple age variable, which is a unit number of times, can significantly affect cancer 
prevention. In order to identify a set of age groups, a combination of parameters with 
appropriate weighting would measure patient age to support current screening methods or 
future biomarker screening to provide information about age-related factors that 
contribute to lung cancer. Therefore, this paper included information such as how long it 
takes for cancer development after exposure to carcinogens that cause mutations. The 
information provided in this student dissertation will benefit future studies on preventive 
screening recommendations, help health professionals enhance their understanding of age 
factors in cancer development, and may help reduce the gap in the lack of effectiveness in 
preventive screening for early detection.  
Implications 
The results of this study have substantial implications for social change and 
suggest age-based recommendation for preventive lung cancer screening for early 
detection of lung cancer. The results also add more support for the establishment of a 
comprehensive policy on preventive screening for early detection of lung cancer that 
aides in alleviating cancer among vulnerable population. Assessing age-associated lung 
cancer will not only fulfill the goal of providing information to support a 
recommendation for early diagnosis and treatment of lung cancer, but may help reduce 
the number of people who die from lung cancer, reduce the burdens of health care costs, 
and provide better health outcomes. Although current methods for early diagnosis and 
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treatment reduce the rate of morbidity and mortality caused by lung cancer, lung cancer is 
still the leading cause of cancer death. This paper concluded by giving information about 
age stratification to help understand the age-related factors that contribute to lung cancer. 
The enhancement in knowledge of age-factors related to lung cancer could provide 
information about the association between age and biomarkers of lung cancer for future 
molecular biological studies. The statistical analyses in this dissertation indicated that 
among all age groups, the stage of lung cancer with the fastest progression was stage 
IV.  Because many studies have found that the incidence of cancer rates increase with age 
(Chen et al., 2019; White et al., 2014), studies that evaluate a combination of factors 
provide a better tool for measuring age-related factors that contribute to lung cancer 
development based on the stages of lung cancer. Future studies are needed to focus on 
biomarkers of lung cancer based on patient age to better understand how age can 
contribute to lung cancer, and to provide supporting information for age-based 
recommendation for early detection of lung cancer. 
Conclusion  
The age at diagnosis and each stage of lung cancer was shown to be statistically 
significant when chi-squared tests were used. The data also indicated low rates in early 
stages (stage I and II) of lung cancer in age groups (45‒49) and (50‒54) years old. 
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Appendix A: Table Showing the Demographic Factors of Lung Cancer 
Table 1. 
Demographic Factors of Lung Cancer  
   
Characteristics Frequency % 
   
Sex   
Women 28,035 44.4 
Men 35,075 55.6 
Total 63,107 100 
Race/Ethnicity 
White 55,049 87.2 
Black 8,058 12.8 
Total 63,107 100.0 
Age group   
(45‒49) years 1,536 2.4 
(50‒54) years 3,831 6.1 
(55‒59) years 6,550 10.4 
(60‒64) years 8,967 14.2 
(65‒69) years 11,548 18.3 
(70‒74) years 11,942 18.9 
(75‒79) years 10,734 17.0 
(80‒84) years 7,999 12.7 
Total 63,107 100.0 
Stage   
I 8,319 13.2 
II 5,943 9.4 
III 15,441 24.5 
IV 33,404 52.9 
Total 63,107 100.0 
   
Geographical regions   
Metropolitan Counties  52,835 83.7 
Non-Metropolitan Counties 10,272 16.3 
Total 63107 100.0 
Note: SEER‒18 Registries Data.  
 
 
